

# Athanasios Dimopoulos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1911858/publications.pdf>

Version: 2024-02-01

1,028  
papers

66,657  
citations

997

114  
h-index

1222

227  
g-index

1044  
all docs

1044  
docs citations

1044  
times ranked

36653  
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology, The</i> , 2014, 15, e538-e548.	10.7	3,343
2	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology, The</i> , 2016, 17, e328-e346.	10.7	1,866
3	Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. <i>New England Journal of Medicine</i> , 2008, 359, 906-917.	27.0	1,787
4	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2015, 33, 2863-2869.	1.6	1,525
5	Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2007, 357, 2123-2132.	27.0	1,365
6	Hematological findings and complications of COVID-19. <i>American Journal of Hematology</i> , 2020, 95, 834-847.	4.1	1,354
7	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 1319-1331.	27.0	1,210
8	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	27.0	1,144
9	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 373, 621-631.	27.0	1,139
10	Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma. <i>New England Journal of Medicine</i> , 1996, 334, 488-493.	27.0	1,030
11	Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors. <i>Journal of Clinical Oncology</i> , 2005, 23, 8580-8587.	1.6	990
12	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011, 117, 4691-4695.	1.4	849
13	Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 110-115.	2.2	841
14	Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2018, 378, 518-528.	27.0	747
15	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2012, 30, 4541-4549.	1.6	735
16	Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. <i>Lancet Oncology, The</i> , 2016, 17, 27-38.	10.7	723
17	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2013, 14, 1055-1066.	10.7	710
18	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 906-917.	27.0	697

#	ARTICLE	IF	CITATIONS
19	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	10.7	695
20	Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1759-1769.	27.0	692
21	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	7.2	664
22	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	1.4	586
23	Oral Selinexorâ€“Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	27.0	460
24	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 2096-2107.	13.7	435
25	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2018, 379, 1811-1822.	27.0	413
26	Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 2259-2266.	1.6	403
27	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. <i>Blood</i> , 2013, 121, 3420-3427.	1.4	385
28	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. <i>Blood</i> , 2011, 117, 4701-4705.	1.4	377
29	The Treatment of Multiple Myeloma. <i>New England Journal of Medicine</i> , 1994, 330, 484-489.	27.0	376
30	International prognostic scoring system for WaldenstrÃ¶m macroglobulinemia. <i>Blood</i> , 2009, 113, 4163-4170.	1.4	366
31	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 4976-4984.	1.6	358
32	Organ-specific manifestations of COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2020, 20, 493-506.	3.6	351
33	Solitary plasmacytoma of bone and asymptomatic multiple myeloma. <i>Blood</i> , 2000, 96, 2037-2044.	1.4	334
34	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	1.6	330
35	Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. <i>Journal of Clinical Oncology</i> , 2015, 33, 657-664.	1.6	330
36	Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1327-1337.	10.7	320

#	ARTICLE	IF	CITATIONS
37	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). <i>Blood</i> , 2011, 118, 4519-4529.	1.4	309
38	International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease. <i>Journal of Clinical Oncology</i> , 2013, 31, 2347-2357.	1.6	307
39	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , The, 2020, 396, 186-197.	13.7	299
40	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. <i>Journal of Clinical Oncology</i> , 2016, 34, 1544-1557.	1.6	294
41	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2018, 378, 2399-2410.	27.0	291
42	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.	3.5	289
43	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. <i>Blood</i> , 2011, 117, 4696-4700.	1.4	285
44	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	1.4	282
45	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. <i>Blood</i> , 2020, 136, 2038-2050.	1.4	281
46	Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis. <i>Journal of Clinical Oncology</i> , 2010, 28, 1031-1037.	1.6	273
47	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.	27.0	268
48	Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2007, 25, 3344-3349.	1.6	264
49	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	10.7	256
50	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 781-794.	10.7	254
51	Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 448-455.	1.6	250
52	Treatment of Waldenström's Macroglobulinemia With Rituximab. <i>Journal of Clinical Oncology</i> , 2002, 20, 2327-2333.	1.6	248
53	Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Haematology</i> , the. 2020, 7, e456-e468.	4.6	244
54	Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 3578-3585.	1.6	241

#	ARTICLE	IF	CITATIONS
55	Emerging treatment strategies for COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2021, 21, 167-179.	3.6	232
56	Diagnosis and Management of Waldenström's Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 1564-1577.	1.6	225
57	Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. <i>Haematologica</i> , 2006, 91, 968-71.	3.5	223
58	Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 728-734.	1.6	221
59	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE) Tj ETQq1 1 0.784314 rgBT /Overlo	10.7	219
60	Pathogenesis of bone disease in multiple myeloma: from bench to bedside. <i>Blood Cancer Journal</i> , 2018, 8, 7.	6.2	219
61	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. <i>Blood</i> , 2018, 131, 301-310.	1.4	216
62	Olive oil intake is inversely related to cancer prevalence: a systematic review and a meta-analysis of 13800 patients and 23340 controls in 19 observational studies. <i>Lipids in Health and Disease</i> , 2011, 10, 127.	3.0	213
63	Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 241-250.	10.7	212
64	Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 120-126.	1.6	207
65	A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5988-5999.	5.2	198
66	Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10%549 patients from the International Myeloma Working Group. <i>Blood</i> , 2008, 111, 4039-4047.	1.4	190
67	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2020, 396, 1563-1573.	13.7	188
68	Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. <i>Lancet Oncology</i> , The, 2010, 11, 1086-1095.	10.7	187
69	Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. <i>Haematologica</i> , 2018, 103, 2088-2096.	3.5	187
70	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 393, 253-264.	13.7	187
71	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. <i>Haematologica</i> , 2014, 99, 232-242.	3.5	185
72	Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). <i>Blood</i> , 2013, 122, 3276-3282.	1.4	180

#	ARTICLE	IF	CITATIONS
73	Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. <i>Haematologica</i> , 2007, 92, 1351-1358.	3.5	179
74	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet</i> , The, 2021, 397, 2361-2371.	13.7	177
75	Current treatment landscape for relapsed and/or refractory multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 42-54.	27.6	175
76	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. <i>Blood Cancer Journal</i> , 2018, 8, 109.	6.2	170
77	Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 953-964.	10.7	169
78	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, 9.	7.0	167
79	Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. <i>Blood</i> , 2008, 112, 4445-4451.	1.4	164
80	Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. <i>Leukemia</i> , 2020, 34, 1875-1884.	7.2	163
81	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 801-812.	10.7	162
82	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. <i>Blood</i> , 2016, 128, 1321-1328.	1.4	161
83	Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. <i>Haematologica</i> , 2007, 92, 546-549.	3.5	160
84	VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 6086-6093.	1.6	154
85	Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. <i>International Journal of Cancer</i> , 2006, 119, 1728-1731.	5.1	153
86	Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy. <i>International Journal of Cancer</i> , 2012, 131, 1466-1471.	5.1	150
87	Risk of disease progression in asymptomatic multiple myeloma. <i>American Journal of Medicine</i> , 1993, 94, 57-61.	1.5	148
88	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146
89	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. <i>Carcinogenesis</i> , 2014, 35, 1012-1019.	2.8	145
90	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016, 128, 497-503.	1.4	144

#	ARTICLE	IF	CITATIONS
91	A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012, 119, 2764-2767.	1.4	143
92	Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5904-5909.	1.6	139
93	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. <i>Blood</i> , 2014, 124, 1404-1411.	1.4	138
94	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3459-3466.	1.6	138
95	Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. <i>American Journal of Hematology</i> , 2021, 96, E257-E259.	4.1	138
96	Systemic IL-15, IFN- $\beta$ , and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. <i>Cell Reports</i> , 2021, 36, 109504.	6.4	137
97	Treatment options for relapsed and refractory multiple myeloma. <i>Blood</i> , 2015, 125, 3085-3099.	1.4	136
98	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
99	VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. <i>International Journal of Cancer</i> , 2012, 130, 857-864.	5.1	134
100	Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. <i>Gynecologic Oncology</i> , 2005, 97, 436-441.	1.4	133
101	Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. <i>Lancet Oncology</i> , The, 2008, 9, 1166-1172.	10.7	131
102	Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1597-1628.	3.4	131
103	Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. <i>Blood</i> , 2021, 137, 3674-3676.	1.4	130
104	Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. <i>The Hematology Journal</i> , 2004, 5, 112-117.	1.4	129
105	Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). <i>Leukemia and Lymphoma</i> , 2006, 47, 2140-2146.	1.3	128
106	Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 8637-8643.	7.0	127
107	Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. <i>Journal of Infection</i> , 2021, 83, 1-16.	3.3	127
108	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. <i>European Journal of Haematology</i> , 2011, 86, 23-31.	2.2	126

#	ARTICLE	IF	CITATIONS
109	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, 102.	6.2	126
110	Treatment of Waldenstrom's Macroglobulinemia With Thalidomide. <i>Journal of Clinical Oncology</i> , 2001, 19, 3596-3601.	1.6	123
111	Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experience. <i>Gynecologic Oncology</i> , 2006, 102, 285-291.	1.4	123
112	Adverse effects of thalidomide administration in patients with neoplastic diseases. <i>American Journal of Medicine</i> , 2004, 117, 508-515.	1.5	122
113	A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. <i>Leukemia</i> , 2020, 34, 224-233.	7.2	122
114	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. <i>Blood</i> , 2016, 127, 713-721.	1.4	121
115	Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , 2016, 3, e506-e515.	4.6	121
116	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT follow-up and post-hoc analyses on progression-free survival and tumour growth. <i>British Journal of Haematology</i> , 2017, 178, 896-905.	2.5	120
117	Systemic therapy in cervical cancer: 30 years in review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 137, 9-17.	4.4	119
118	The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. <i>Cancer</i> , 2010, 116, 3807-3814.	4.1	118
119	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT trial. <i>Cancer</i> , 2018, 124, 4032-4043.	4.1	118
120	Fludarabine therapy in Waldenström's macroglobulinemia. <i>American Journal of Medicine</i> , 1993, 95, 49-52.	1.5	116
121	A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 42-49.	4.1	116
122	SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions. <i>Science of the Total Environment</i> , 2022, 804, 150151.	8.0	116
123	Oncology during the COVID-19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients (Review). <i>Oncology Letters</i> , 2020, 20, 441-447.	1.8	115
124	Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives. <i>Journal of Clinical Oncology</i> , 2003, 21, 4444-4454.	1.6	113
125	High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. <i>European Journal of Haematology</i> , 2010, 85, 114-119.	2.2	113
126	Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. <i>Blood</i> , 2013, 121, 318-328.	1.4	112



#	ARTICLE	IF	CITATIONS
127	Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. <i>Haematologica</i> , 2017, 102, 43-51.	3.5	112
128	Primary Ovarian Non-Hodgkin's Lymphoma: Outcome after Treatment with Combination Chemotherapy. <i>Gynecologic Oncology</i> , 1997, 64, 446-450.	1.4	111
129	A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2013, 160, 649-659.	2.5	111
130	Advances in Imaging and the Management of Myeloma Bone Disease. <i>Journal of Clinical Oncology</i> , 2011, 29, 1907-1915.	1.6	110
131	Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3841-3847.	1.6	110
132	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	1.4	110
133	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018, 103, 197-211.	3.5	110
134	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020, 38, 2380-2389.	1.6	110
135	Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. <i>Haematologica</i> , 2010, 95, 1738-1744.	3.5	109
136	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	7.2	109
137	Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. <i>Urology</i> , 2004, 64, 479-484.	1.0	108
138	Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. <i>Blood</i> , 2015, 126, 1392-1394.	1.4	108
139	Prognostic value of cytogenetics in multiple myeloma. <i>British Journal of Haematology</i> , 1998, 101, 189-194.	2.5	107
140	The prevalence of bcl-2, p53, and ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. <i>Human Pathology</i> , 1998, 29, 146-154.	2.0	107
141	Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 380-383.	1.4	107
142	2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenström's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 243-247.	2.2	106
143	Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC). <i>Cancer</i> , 2011, 117, 5500-5508.	4.1	106
144	Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care. <i>Oncologist</i> , 2012, 17, 239-249.	3.7	105

#	ARTICLE	IF	CITATIONS
145	Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 15885-15909.	4.1	105
146	Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. <i>European Journal of Haematology</i> , 2009, 82, 426-432.	2.2	104
147	Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. <i>Trends in Molecular Medicine</i> , 2022, 28, 542-554.	6.7	104
148	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. <i>Blood Cancer Journal</i> , 2021, 11, 138.	6.2	103
149	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2020, 38, 3252-3260.	1.6	102
150	Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 302-306.	1.4	101
151	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. <i>Blood</i> , 2010, 116, 3743-3750.	1.4	101
152	Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations. <i>Journal of Clinical Oncology</i> , 2010, 28, 690-697.	1.6	101
153	Proteasome dysfunction in <i>Drosophila</i> signals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging. <i>Aging Cell</i> , 2013, 12, 802-813.	6.7	98
154	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , 2020, 7, e827-e837.	4.6	96
155	Monoclonal gammopathy of undetermined significance: a consensus statement. <i>British Journal of Haematology</i> , 2010, 150, 28-38.	2.5	95
156	Proteasome inhibitor associated thrombotic microangiopathy. <i>American Journal of Hematology</i> , 2016, 91, E348-52.	4.1	95
157	Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). <i>British Journal of Haematology</i> , 2004, 126, 686-689.	2.5	93
158	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. <i>Lancet Oncology</i> , 2021, 22, e119-e130.	10.7	92
159	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	3.7	90
160	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. <i>Blood Cancer Journal</i> , 2020, 10, 91.	6.2	90
161	Cardiac and renal complications of carfilzomib in patients with multiple myeloma. <i>Blood Advances</i> , 2017, 1, 449-454.	5.2	89
162	A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. <i>Blood</i> , 2012, 119, 5384-5390.	1.4	88

#	ARTICLE	IF	CITATIONS
163	Recent advances in the management of <sc>AL</sc> Amyloidosis. British Journal of Haematology, 2016, 172, 170-186.	2.5	88
164	Myeloma bone disease: from biology findings to treatment approaches. Blood, 2019, 133, 1534-1539.	1.4	88
165	Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectives. TrAC - Trends in Analytical Chemistry, 2021, 134, 116125.	11.4	88
166	Primary Lymphoma of the Prostate: Good Outcome with Doxorubicin-Based Combination Chemotherapy. Journal of Urology, 1995, 153, 1852-1854.	0.4	86
167	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica, 2018, 103, 1772-1784.	3.5	86
168	Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective. Oncologist, 2010, 15, 6-25.	3.7	85
169	Consensus on the utility of bone markers in the malignant bone disease setting. Critical Reviews in Oncology/Hematology, 2011, 80, 411-432.	4.4	84
170	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia, 2018, 32, 1697-1712.	7.2	83
171	The Mediterranean Diet in Cancer Prevention: A Review. Journal of Medicinal Food, 2011, 14, 1065-1078.	1.5	82
172	Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood, 2019, 133, 710-723.	1.4	82
173	Paclitaxel and Cisplatin in Advanced or Recurrent Carcinoma of the Endometrium: Long-Term Results of a Phase II Multicenter Study. Gynecologic Oncology, 2000, 78, 52-57.	1.4	81
174	Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients. American Journal of Hematology, 2012, 87, 861-864.	4.1	81
175	Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. Radiology, 2017, 282, 484-493.	7.3	81
176	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia, 2018, 32, 1883-1898.	7.2	81
177	Association of <sc>COVID</sc>-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection. European Journal of Heart Failure, 2021, 23, 1916-1926.	7.1	81
178	Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. Cancer, 1992, 69, 66-71.	4.1	80
179	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncology, The, 2022, 23, 65-76.	10.7	80
180	Treatment of Pancreatic Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor: A Multicenter Phase II Study. Journal of Clinical Oncology, 1999, 17, 1779-1779.	1.6	79

#	ARTICLE	IF	CITATIONS
181	High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. <i>Blood</i> , 2019, 133, 1217-1221.	1.4	79
182	Oral estramustine and oral etoposide for hormone-refractory prostate cancer. <i>Urology</i> , 1997, 50, 754-758.	1.0	78
183	The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2006, 106, 297-303.	4.1	78
184	Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan+prednisone vs. melphalan+prednisone in the phase III VISTA trial in multiple myeloma. <i>European Journal of Haematology</i> , 2011, 86, 372-384.	2.2	77
185	Thyroid hormone and recovery of cardiac function in patients with acute myocardial infarction: a strong association?. <i>European Journal of Endocrinology</i> , 2011, 165, 107-114.	3.7	77
186	Patterns of pharmaceuticals use during the first wave of COVID-19 pandemic in Athens, Greece as revealed by wastewater-based epidemiology. <i>Science of the Total Environment</i> , 2021, 798, 149014.	8.0	76
187	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 17.	6.2	75
188	Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2008, 49, 890-895.	1.3	74
189	Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. <i>American Journal of Hematology</i> , 2016, 91, 499-502.	4.1	73
190	Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. <i>Haematologica</i> , 2017, 102, 593-599.	3.5	72
191	Extended Rituximab Therapy for Previously Untreated Patients with Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 163-166.	2.1	71
192	Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 3609-3617.	1.6	71
193	Treatment of light chain deposition disease with bortezomib and dexamethasone. <i>Haematologica</i> , 2009, 94, 300-302.	3.5	70
194	Emerging therapies for the treatment of relapsed or refractory multiple myeloma. <i>European Journal of Haematology</i> , 2011, 86, 1-15.	2.2	70
195	Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3921-3930.	1.6	70
196	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. <i>Haematologica</i> , 2015, 100, 1327-1333.	3.5	68
197	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	7.2	68
198	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	2.5	67

#	ARTICLE	IF	CITATIONS
199	Treatment of relapsed and refractory multiple myeloma in the era of novel agents. <i>Cancer Treatment Reviews</i> , 2011, 37, 266-283.	7.7	66
200	Cardio-oncology: A Focus on Cardiotoxicity. <i>European Cardiology Review</i> , 2018, 13, 64.	2.2	65
201	How I treat Waldenström macroglobulinemia. <i>Blood</i> , 2019, 134, 2022-2035.	1.4	65
202	Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1403-1411.	1.6	65
203	A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. <i>Cancer</i> , 2002, 94, 452-458.	4.1	64
204	Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. <i>Leukemia Research</i> , 2010, 34, 1395-1397.	0.8	64
205	Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: The impact of inflammatory process and oxidative stress. <i>Atherosclerosis</i> , 2011, 214, 151-157.	0.8	63
206	Dickkopf-1: a suitable target for the management of myeloma bone disease. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 839-848.	3.4	62
207	Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. <i>Oncologist</i> , 2017, 22, 667-679.	3.7	62
208	BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. <i>Blood</i> , 2017, 129, 456-459.	1.4	62
209	Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNOVATE Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 52-62.	1.6	62
210	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 175, 77-86.	2.5	61
211	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e401-e419.	0.4	61
212	Change in the chemical content of untreated wastewater of Athens, Greece under COVID-19 pandemic. <i>Science of the Total Environment</i> , 2021, 799, 149230.	8.0	61
213	Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. <i>Haematologica</i> , 2009, 94, 372-379.	3.5	60
214	Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2012, 113, 234-238.	0.4	60
215	Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 38-43.	0.4	59
216	Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. <i>Blood Cancer Journal</i> , 2018, 8, 95.	6.2	59

#	ARTICLE	IF	CITATIONS
217	A review of the impact of weather and climate variables to COVID-19: In the absence of public health measures high temperatures cannot probably mitigate outbreaks. <i>Science of the Total Environment</i> , 2021, 768, 144578.	8.0	59
218	Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. <i>Cancer</i> , 2005, 103, 2629-2635.	4.1	58
219	Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone. <i>Journal of Clinical Oncology</i> , 2010, 28, 132-135.	1.6	58
220	Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib+melfalan+prednisone in the phase III VISTA study. <i>American Journal of Hematology</i> , 2015, 90, 314-319.	4.1	58
221	Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. <i>British Journal of Haematology</i> , 2017, 177, 404-413.	2.5	58
222	Investigation and management of IgM and Waldenström's associated peripheral neuropathies: recommendations from the IWWM consensus panel. <i>British Journal of Haematology</i> , 2017, 176, 728-742.	2.5	58
223	Somatic mutations of adenomatous polyposis coli gene and nuclear $\beta$ -catenin accumulation have prognostic significance in invasive urothelial carcinomas: Evidence for Wnt pathway implication. <i>International Journal of Cancer</i> , 2009, 124, 103-108.	5.1	57
224	Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. <i>Haematologica</i> , 2013, 98, 784-788.	3.5	57
225	Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. <i>Leukemia and Lymphoma</i> , 2014, 55, 2018-2023.	1.3	57
226	Treatment of Waldenström's Macroglobulinemia with the Combination of Fludarabine and Cyclophosphamide. <i>Leukemia and Lymphoma</i> , 2003, 44, 993-996.	1.3	56
227	Validation of the International Prognostic Scoring System (IPSS) for Waldenström's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). <i>Leukemia Research</i> , 2010, 34, 1340-1343.	0.8	56
228	Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. <i>American Journal of Hematology</i> , 2014, 89, 145-150.	4.1	56
229	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4030-4041.	1.6	56
230	Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. <i>Leukemia Research</i> , 2010, 34, 1111-1118.	0.8	55
231	Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. <i>Hematological Oncology</i> , 2013, 31, 96-102.	1.7	55
232	Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. <i>American Journal of Hematology</i> , 2015, 90, E60-5.	4.1	55
233	Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2035-2043.	1.6	55
234	Successful Conservative Treatment of Neutropenic Enterocolitis Complicating Taxane-Based Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 309-313.	1.3	55

#	ARTICLE	IF	CITATIONS
235	Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel. <i>PLoS ONE</i> , 2012, 7, e37946.	2.5	54
236	Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients. <i>American Journal of Hematology</i> , 2014, 89, 803-808.	4.1	54
237	The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. <i>Blood</i> , 2018, 131, 464-467.	1.4	54
238	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	7.2	54
239	Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. <i>Blood Advances</i> , 2020, 4, 830-844.	5.2	54
240	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 416-427.	10.7	54
241	Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: A randomized placebo-controlled study. <i>Atherosclerosis</i> , 2010, 210, 194-198.	0.8	53
242	A predictive model for risk of early grade 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. <i>Leukemia</i> , 2018, 32, 1404-1413.	7.2	53
243	A revised international prognostic score system for Waldenström's macroglobulinemia. <i>Leukemia</i> , 2019, 33, 2654-2661.	7.2	53
244	The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). <i>Blood Cancer Journal</i> , 2019, 9, 27.	6.2	53
245	SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors. <i>European Journal of Internal Medicine</i> , 2021, 89, 87-96.	2.2	53
246	Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. <i>BMC Medicine</i> , 2021, 19, 208.	5.5	52
247	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8000-8000.	1.6	52
248	Rituximab therapy in monoclonal IgM-related neuropathies. <i>Leukemia and Lymphoma</i> , 2006, 47, 859-864.	1.3	51
249	The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. <i>Cancer Treatment Reviews</i> , 2016, 43, 58-66.	7.7	51
250	Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. <i>Urology</i> , 1998, 52, 56-60.	1.0	50
251	Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 563-577.e3.	0.4	50
252	Treatment of Relapsed/Refractory Multiple Myeloma. <i>Seminars in Hematology</i> , 2009, 46, 143-157.	3.4	49

#	ARTICLE	IF	CITATIONS
253	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2021, 137, 1154-1165.	1.4	49
254	Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. <i>Endocrine</i> , 2021, 74, 478-497.	2.3	49
255	Multiple myeloma in elderly patients: prognostic factors and outcome. <i>European Journal of Haematology</i> , 2005, 75, 370-375.	2.2	48
256	European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses. <i>Oncologist</i> , 2012, 17, 592-606.	3.7	48
257	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 609-619.	2.5	48
258	Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. <i>Leukemia Research</i> , 2013, 37, 829-837.	0.8	48
259	Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 737-748.	2.4	48
260	Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. <i>American Journal of Hematology</i> , 2017, 92, 632-639.	4.1	48
261	A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. <i>Haematologica</i> , 2020, 105, 201-208.	3.5	48
262	Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 522-530.e1.	0.4	47
263	Prunart Renal Lymphoma: A Clinical and Radiological Study. <i>Journal of Urology</i> , 1996, 155, 1865-1867.	0.4	46
264	The evolving role of lenalidomide in the treatment of hematologic malignancies. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 497-509.	1.8	46
265	Biweekly Carboplatin/Gemcitabine in Patients with Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: Report of Efficacy, Quality of Life and Geriatric Assessment. <i>Oncology</i> , 2007, 73, 290-297.	1.9	46
266	Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study. <i>Clinical Colorectal Cancer</i> , 2016, 15, e133-e140.	2.3	46
267	Efficacy of Panobinostat for the Treatment of Multiple Myeloma. <i>Journal of Oncology</i> , 2020, 2020, 1-11.	1.3	46
268	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 142-154.	10.7	46
269	Pathogenesis and management of myeloma bone disease. <i>Expert Review of Hematology</i> , 2009, 2, 385-398.	2.2	45
270	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. <i>HemaSphere</i> , 2021, 5, e528.	2.7	45



#	ARTICLE	IF	CITATIONS
271	Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem cell transplantation: Results of a single institution, randomized phase 2 trial. <i>American Journal of Hematology</i> , 2010, 85, 863-867.	4.1	44
272	Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-15.	3.3	44
273	Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. <i>Haematologica</i> , 2015, 100, e446-e449.	3.5	44
274	Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2015, 100, 1334-1339.	3.5	44
275	Diagnostic work-up and specific causes of acute kidney injury. <i>Intensive Care Medicine</i> , 2017, 43, 829-840.	8.2	44
276	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. <i>Blood</i> , 2018, 131, 1568-1575.	1.4	44
277	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. <i>Cancers</i> , 2021, 13, 4480.	3.7	44
278	WALDENSTRÖM'S MACROGLOBULINEMIA. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 1351-1366.	2.2	43
279	No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years. <i>American Journal of Hematology</i> , 2011, 86, 479-483.	4.1	43
280	Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. <i>Annals of Hematology</i> , 2015, 94, 2033-2042.	1.8	43
281	Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. <i>Leukemia</i> , 2021, 35, 562-572.	7.2	43
282	Angiogenesis in human cancer: implications in cancer therapy. <i>European Journal of Internal Medicine</i> , 2003, 14, 459-469.	2.2	42
283	Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2006, 96, 251-261.	2.5	42
284	The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens. <i>Haematologica</i> , 2008, 93, 1420-1422.	3.5	42
285	Multiple myeloma: Role of autologous transplantation. <i>Cancer Treatment Reviews</i> , 2020, 82, 101929.	7.7	42
286	The Emerging Role of Convalescent Plasma in the Treatment of COVID-19. <i>HemaSphere</i> , 2020, 4, e409.	2.7	42
287	A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study. <i>BMC Medicine</i> , 2011, 9, 10.	5.5	41
288	The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e407-e417.	3.8	41

#	ARTICLE	IF	CITATIONS
289	Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. <i>Lancet Haematology</i> , 2018, 5, e299-e309.	4.6	41
290	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. <i>Haematologica</i> , 2020, 105, 468-477.	3.5	41
291	Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 5-6.	1.4	41
292	How to Manage Neutropenia in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 5-11.	0.4	40
293	Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. <i>American Journal of Hematology</i> , 2013, 88, 765-770.	4.1	40
294	Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 519-530.	0.4	40
295	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. <i>Leukemia</i> , 2018, 32, 2617-2625.	7.2	40
296	MR imaging of complex tail-gut cysts. <i>Clinical Radiology</i> , 1999, 54, 118-122.	1.1	39
297	Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. <i>Gynecologic Oncology</i> , 2004, 95, 695-700.	1.4	39
298	Treatment of Waldenström's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression. <i>Leukemia and Lymphoma</i> , 2004, 45, 2057-2061.	1.3	39
299	Waldenström's macroglobulinemia. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 747-765.	1.7	39
300	Increased Serum Lactate Dehydrogenase Should Be Included Among the Variables That Define Very-High-Risk Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 409-413.	0.4	39
301	Prognostic Significance of Cytoreductive Nephrectomy in Patients With Synchronous Metastases From Renal Cell Carcinoma Treated With First-Line Sunitinib: A European Multiinstitutional Study. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 373-383.	1.9	39
302	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. <i>Blood Cancer Journal</i> , 2018, 8, 46.	6.2	39
303	Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2019, 98, 2139-2150.	1.8	39
304	Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e212-e219.	2.4	39
305	Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. <i>Microorganisms</i> , 2020, 8, 1885.	3.6	39
306	Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression. <i>Cancer Treatment Reviews</i> , 2020, 88, 102046.	7.7	39

#	ARTICLE	IF	CITATIONS
307	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. <i>Blood Advances</i> , 2021, 5, 4398-4405.	5.2	39
308	Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment. <i>Clinical Cancer Research</i> , 2012, 18, 2145-2163.	7.0	38
309	Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1680-1690.	3.4	38
310	Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Cells</i> , 2021, 10, 1942.	4.1	38
311	Diabetes and COVID-19; A Bidirectional Interplay. <i>Frontiers in Endocrinology</i> , 2022, 13, 780663.	3.5	38
312	Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. <i>British Journal of Haematology</i> , 2007, 137, 560-568.	2.5	37
313	Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenström macroglobulinemia. <i>Blood</i> , 2011, 117, 2918-2923.	1.4	37
314	The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC. <i>European Journal of Haematology</i> , 2013, 91, n/a-n/a.	2.2	37
315	Optimal use of bisphosphonates in patients with multiple myeloma. <i>Blood</i> , 2013, 121, 3325-3328.	1.4	37
316	Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. <i>Leukemia and Lymphoma</i> , 2014, 55, 1489-1497.	1.3	37
317	Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. <i>Blood</i> , 2016, 128, 405-409.	1.4	37
318	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. <i>European Journal of Haematology</i> , 2017, 99, 409-414.	2.2	37
319	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. <i>Blood Advances</i> , 2019, 3, 3002-3009.	5.2	37
320	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 646-646.	1.4	37
321	Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma. <i>British Journal of Haematology</i> , 1993, 83, 240-244.	2.5	36
322	Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. <i>Urology</i> , 2004, 63, 120-125.	1.0	36
323	Alcohol consumption and risk of hematological malignancies: A meta-analysis of prospective studies. <i>International Journal of Cancer</i> , 2018, 143, 486-495.	5.1	36
324	Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studies. <i>International Journal of Cancer</i> , 2019, 145, 347-359.	5.1	36

#	ARTICLE	IF	CITATIONS
325	Late-onset hematological complications post COVID-19: An emerging medical problem for the hematologist. <i>American Journal of Hematology</i> , 2022, 97, 119-128.	4.1	36
326	The International Staging System for Multiple Myeloma is Applicable in Symptomatic Waldenstrom's Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 1809-1813.	1.3	35
327	Clinicopathological features of ovarian carcinosarcomas: a single institution experience. <i>Gynecologic Oncology</i> , 2005, 96, 136-142.	1.4	35
328	Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor p27 Independently Predict for Survival in Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 8384-8390.	7.0	35
329	Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. <i>Blood Reviews</i> , 2009, 23, 87-93.	5.7	35
330	Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. <i>Haematologica</i> , 2013, 98, 1264-1272.	3.5	35
331	Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. <i>Blood Cancer Journal</i> , 2018, 8, 31.	6.2	35
332	Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. <i>Leukemia</i> , 2021, 35, 1722-1731.	7.2	35
333	DNA damage, tumor mutational load and their impact on immune responses against cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 264-264.	1.7	35
334	Bone Lesions with Soft-Tissue Mass: Magnetic Resonance Imaging Diagnosis of Lymphomatous Involvement of the Bone Marrow Versus Multiple Myeloma and Bone Metastases. <i>Leukemia and Lymphoma</i> , 1999, 34, 179-184.	1.3	34
335	Fulvestrant and male breast cancer: a pooled analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 269-275.	2.5	34
336	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. <i>Drugs</i> , 2016, 76, 853-867.	10.9	34
337	Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. <i>Expert Review of Hematology</i> , 2020, 13, 421-433.	2.2	34
338	Immunogenic Cell Death, DAMPs and Prothymosin $\hat{\pm}$ as a Putative Anticancer Immune Response Biomarker. <i>Cells</i> , 2022, 11, 1415.	4.1	34
339	Light chain deposition disease of the liver without renal involvement in a patient with multiple myeloma related to liver failure and rapid fatal outcome. <i>Digestive Diseases and Sciences</i> , 2002, 47, 730-734.	2.3	33
340	Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. <i>Haematologica</i> , 2007, 92, 1505-1512.	3.5	33
341	Staging and prognostication of multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 21-31.	2.2	33
342	The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group. <i>American Journal of Hematology</i> , 2014, 89, 34-40.	4.1	33

#	ARTICLE	IF	CITATIONS
343	Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. <i>Haematologica</i> , 2015, 100, 100-106.	3.5	33
344	Aberrant DNA Damage Response Pathways May Predict the Outcome of Platinum Chemotherapy in Ovarian Cancer. <i>PLoS ONE</i> , 2015, 10, e0117654.	2.5	33
345	Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. <i>Haematologica</i> , 2016, 101, 363-370.	3.5	33
346	Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. <i>Journal of Hematology and Oncology</i> , 2018, 11, 49.	17.0	33
347	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	2.7	33
348	Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. <i>Blood</i> , 2019, 133, 147-155.	1.4	33
349	Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. <i>Rheumatology International</i> , 2020, 40, 1353-1360.	3.0	33
350	Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays. <i>Scientific Reports</i> , 2021, 11, 6614.	3.3	33
351	Combination of Ifosfamide, Paclitaxel, and Cisplatin for the Treatment of Metastatic and Recurrent Carcinoma of the Uterine Cervix: A Phase II Study of the Hellenic Cooperative Oncology Group. <i>Gynecologic Oncology</i> , 2002, 85, 476-482.	1.4	32
352	Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. <i>International Journal of Cancer</i> , 2012, 130, 735-742.	5.1	32
353	Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 23.	6.2	32
354	Early and late endocrine complications of COVID-19. <i>Endocrine Connections</i> , 2021, 10, R229-R239.	1.9	32
355	Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. <i>ESMO Open</i> , 2022, 7, 100403.	4.5	32
356	Targeted therapies in multiple myeloma. <i>Targeted Oncology</i> , 2009, 4, 23-36.	3.6	31
357	Study of T Lymphocytes Infiltrating Peritoneal Metastases in Advanced Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1329-1334.	2.5	31
358	CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. <i>Haematologica</i> , 2011, 96, 1557-1559.	3.5	31
359	Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. <i>European Journal of Haematology</i> , 2014, 92, 308-312.	2.2	31
360	Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. <i>Life</i> , 2020, 10, 214.	2.4	31

#	ARTICLE	IF	CITATIONS
361	The emerging role of BET inhibitors in breast cancer. <i>Breast</i> , 2020, 53, 152-163.	2.2	31
362	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1049-1061.	1.8	31
363	SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. <i>HemaSphere</i> , 2021, 5, e547.	2.7	31
364	Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 86.	17.0	31
365	Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS8055-TPS8055.	1.6	31
366	The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e407-e417.	3.8	31
367	Dosing of thioTEPA for myeloablative therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 37, 155-160.	2.3	30
368	Macrofocal multiple myeloma in young patients: A distinct entity with favorable prognosis. <i>Leukemia and Lymphoma</i> , 2006, 47, 1553-1556.	1.3	30
369	Sclerostin: a possible target for the management of cancer-induced bone disease. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 761-769.	3.4	30
370	Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome. <i>Haematologica</i> , 2012, 97, 1699-1703.	3.5	30
371	Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. <i>OncoTargets and Therapy</i> , 2013, 6, 531.	2.0	30
372	Clinical characteristics of patients with relapsed multiple myeloma. <i>Cancer Treatment Reviews</i> , 2015, 41, 827-835.	7.7	30
373	Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. <i>Clinical and Experimental Medicine</i> , 2022, 22, 319-323.	3.6	30
374	DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7. <i>Blood</i> , 2016, 128, 1214-1225.	1.4	29
375	A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 153-161.	1.3	29
376	Management of uterine sarcomas and prognostic indicators: real world data from a single-institution. <i>BMC Cancer</i> , 2018, 18, 1247.	2.6	29
377	Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 42.	6.2	29
378	Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial). <i>Blood</i> , 2016, 128, 673-673.	1.4	29

#	ARTICLE	IF	CITATIONS
379	Discordant Response or Progression in Patients with Myeloma Treated with Thalidomide-based Regimens. <i>Leukemia and Lymphoma</i> , 2004, 45, 113-116.	1.3	28
380	Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2007, 104, 580-585.	1.4	28
381	Prognostication in Young and Old Patients with Waldenström's Macroglobulinemia: Importance of the International Prognostic Scoring System and of Serum Lactate Dehydrogenase. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 50-52.	1.4	28
382	Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. <i>European Journal of Haematology</i> , 2010, 85, 1-5.	2.2	28
383	Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era. <i>European Journal of Haematology</i> , 2012, 89, 10-15.	2.2	28
384	Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point. <i>Haematologica</i> , 2015, 100, e328-30.	3.5	28
385	Current treatments for renal failure due to multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2165-2177.	1.8	28
386	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. <i>Oncologist</i> , 2016, 21, 333-342.	3.7	28
387	Prognostic factors for multiple myeloma in the era of novel therapies. <i>Expert Review of Hematology</i> , 2018, 11, 863-879.	2.2	28
388	Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. <i>HemaSphere</i> , 2020, 4, e454.	2.7	28
389	Prognostic role of microRNAs in breast cancer: A systematic review. <i>Oncotarget</i> , 2019, 10, 7156-7178.	1.8	28
390	Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. <i>Blood</i> , 2022, 139, 1409-1412.	1.4	28
391	Myocardial work and vascular dysfunction are partially improved at 12 months after COVID-19 infection. <i>European Journal of Heart Failure</i> , 2022, 24, 727-729.	7.1	28
392	Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. <i>Haematologica</i> , 2008, 93, 451-454.	3.5	27
393	Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 3929-3938.	3.6	27
394	Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. <i>BMC Cancer</i> , 2010, 10, 45.	2.6	27
395	Response to bortezomib of a patient with scleromyxedema refractory to other therapies. <i>Leukemia Research</i> , 2011, 35, e209-e211.	0.8	27
396	Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. <i>BMC Cancer</i> , 2013, 13, 163.	2.6	27

#	ARTICLE	IF	CITATIONS
397	Current treatments for renal failure due to multiple myeloma. Expert Opinion on Pharmacotherapy, 2013, 14, 1477-1495.	1.8	27
398	Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases. PLoS ONE, 2013, 8, e58182.	2.5	27
399	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leukemia and Lymphoma, 2016, 57, 2833-2838.	1.3	27
400	Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM). Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e26-e27.	0.4	27
401	COVID-19: time to flatten the infodemic curve. Clinical and Experimental Medicine, 2021, 21, 161-165.	3.6	27
402	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. Haematologica, 2021, 106, 2054-2065.	3.5	27
403	Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688). Blood, 2019, 134, LBA-6-LBA-6.	1.4	27
404	Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866). Blood, 2015, 126, 4250-4250.	1.4	27
405	The Expanding Role of Fludarabine in Hematologic Malignancies. Leukemia and Lymphoma, 1994, 14, 11-16.	1.3	26
406	High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leukemia Research, 2010, 34, 399-402.	0.8	26
407	Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications. Cancer Immunology, Immunotherapy, 2011, 60, 305-317.	4.2	26
408	Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective. Oncologist, 2011, 16, 388-403.	3.7	26
409	VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 329-334.e1.	0.4	26
410	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Viruses, 2021, 13, 26.	3.3	26
411	A Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix. Cancer, 1997, 79, 2391-2395.	4.1	25
412	Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opinion on Investigational Drugs, 2005, 14, 45-55.	4.1	25
413	Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Supportive Care in Cancer, 2015, 23, 2045-2051.	2.2	25
414	Emerging antibodies for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs, 2016, 21, 225-237.	2.4	25



#	ARTICLE	IF	CITATIONS
415	All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>European Journal of Cancer</i> , 2019, 106, 89-98.	2.8	25
416	High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. <i>Vaccines</i> , 2021, 9, 712.	4.4	25
417	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	1.6	25
418	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. <i>Life</i> , 2021, 11, 1077.	2.4	25
419	Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 793953.	4.8	25
420	Treatment of Langerhans Cell Histiocytosis with 2 Chlorodeoxyadenosine. <i>Leukemia and Lymphoma</i> , 1997, 25, 187-189.	1.3	24
421	Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group. <i>European Journal of Haematology</i> , 2005, 75, 124-129.	2.2	24
422	Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). <i>Cancer Science</i> , 2008, 99, 2224-2229.	3.9	24
423	How lenalidomide is changing the treatment of patients with multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, S23-S35.	4.4	24
424	Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2017, 58, 1832-1839.	1.3	24
425	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 234-241.	3.0	24
426	Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3245.	3.7	24
427	Waldenström Macroglobulinemia Presenting as a Renal or Perirenal Mass: Clinical and Radiographic Features. <i>Leukemia and Lymphoma</i> , 1995, 17, 331-334.	1.3	23
428	Outpatient Treatment of Neutropenic Fever with Oral Antibiotics and Granulocyte Colony-Stimulating Factor. <i>Oncology</i> , 1999, 57, 127-130.	1.9	23
429	Extent of Damage and Repair in the p53 Tumor-Suppressor Gene After Treatment of Myeloma Patients With High-Dose Melphalan and Autologous Blood Stem-Cell Transplantation Is Individualized and May Predict Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2005, 23, 4381-4389.	1.6	23
430	Association between Transcriptional Activity, Local Chromatin Structure, and the Efficiencies of Both Subpathways of Nucleotide Excision Repair of Melphalan Adducts. <i>Cancer Research</i> , 2009, 69, 4424-4433.	0.9	23
431	Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation. <i>European Journal of Haematology</i> , 1991, 47, 371-376.	2.2	23
432	Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, S13-S23.	4.4	23

#	ARTICLE	IF	CITATIONS
433	Tobacco smoking and risk of multiple myeloma: A meta-analysis of 40 observational studies. <i>International Journal of Cancer</i> , 2013, 132, 2413-2431.	5.1	23
434	An overview of the role of carfilzomib in the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1883-1897.	1.8	23
435	Consumption of fruits, vegetables, and risk of hematological malignancies: a systematic review and meta-analysis of prospective studies. <i>Leukemia and Lymphoma</i> , 2018, 59, 434-447.	1.3	23
436	Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. <i>Blood Cancer Journal</i> , 2018, 8, 102.	6.2	23
437	Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m <sup>2</sup> vs. twice-weekly 27 mg/m <sup>2</sup> carfilzomib (randomized A.R.R.O.W. study). <i>Leukemia</i> , 2019, 33, 2934-2946.	7.2	23
438	The Genomic Profile of Pregnancy-Associated Breast Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2020, 10, 1773.	2.8	23
439	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 445-452.	0.4	23
440	Clinical perspectives of BET inhibition in ovarian cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 237-249.	4.4	23
441	International Prognostic Scoring System (IPSS) for Waldenström's Macroglobulinemia (WM). <i>Blood</i> , 2006, 108, 127-127.	1.4	23
442	Treating ALK-positive non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 141-141.	1.7	23
443	Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e403-e414.	4.6	23
444	Multifocal Extranodal Non-Hodgkin Lymphoma: A Clinicopathologic Study of 37 Cases in Greece, a Hellenic Cooperative Oncology Group Study. <i>Oncologist</i> , 2005, 10, 734-738.	3.7	22
445	Prognostic Value of Serum Î² <sub>2</sub> -Microglobulin in Patients with Waldenström's Macroglobulinemia Requiring Treatment. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 205-209.	1.4	22
446	Mantle-Cell Lymphoma (Multiple Lymphomatous Polyposis) of the Entire GI Tract. <i>Journal of Clinical Oncology</i> , 2008, 26, 1555-1557.	1.6	22
447	Intermittent Docetaxel Chemotherapy in Patients With Castrate-resistant Prostate Cancer. <i>Urology</i> , 2011, 77, 682-687.	1.0	22
448	Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. <i>Haematologica</i> , 2015, 100, e63-e67.	3.5	22
449	Evidence of a Redox-Dependent Regulation of Immune Responses to Exercise-Induced Inflammation. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-19.	4.0	22
450	Expression of Î±5-integrin, Î±7-integrin, Î±-cadherin, and N-cadherin in localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 165.e11-165.e18.	1.6	22

#	ARTICLE	IF	CITATIONS
451	Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. <i>Leukemia and Lymphoma</i> , 2017, 58, 2501-2504.	1.3	22
452	Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. <i>Circulation Research</i> , 2019, 125, 744-758.	4.5	22
453	Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2020, 39, 723-730.	1.4	22
454	Next generation flow cytometry for MRD detection in patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 19-23.	3.0	22
455	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.	3.5	22
456	Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 40-51.	1.6	22
457	Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up. <i>Blood</i> , 2015, 126, 28-28.	1.4	22
458	The Development of an Angiogenic Protein "Signature" in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling. <i>PLoS ONE</i> , 2016, 11, e0156403.	2.5	22
459	Defining Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 107-109.	2.2	21
460	Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. <i>DNA Repair</i> , 2006, 5, 972-985.	2.8	21
461	Prostate Cancer with Metastasis to the Omentum and Massive Ascites: A Rare Manifestation of a Common Disease. <i>Onkologie</i> , 2009, 32, 758-761.	0.8	21
462	Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. <i>International Journal of Hematology</i> , 2012, 96, 254-262.	1.6	21
463	Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM03 trial for pomalidomide plus low-dose dexamethasone. <i>British Journal of Haematology</i> , 2015, 168, 820-823.	2.5	21
464	A review of the venous thrombotic issues associated with multiple myeloma. <i>Expert Review of Hematology</i> , 2016, 9, 695-706.	2.2	21
465	Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. <i>British Journal of Haematology</i> , 2017, 177, 441-448.	2.5	21
466	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017, 99, 199-206.	2.2	21
467	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. <i>American Journal of Hematology</i> , 2019, 94, 400-407.	4.1	21
468	Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. <i>Blood Cancer Journal</i> , 2020, 10, 109.	6.2	21

#	ARTICLE	IF	CITATIONS
469	The COVID-19 Pandemic and the Need for an Integrated and Equitable Approach: An International Expert Consensus Paper. <i>Thrombosis and Haemostasis</i> , 2021, 121, 992-1007.	3.4	21
470	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. <i>Biomedicines</i> , 2022, 10, 338.	3.2	21
471	Rising Serum Lactate Dehydrogenase Often Caused by Granulocyte-or Granulocyte-Macrophage Colony Stimulating Factor and not Tumor Progression in Patients with Lymphoma or Myeloma. <i>Leukemia and Lymphoma</i> , 1995, 17, 473-477.	1.3	20
472	Wegener's Granulomatosis Presenting as a Renal Mass. <i>Urology</i> , 2008, 71, 547.e1-547.e2.	1.0	20
473	Mitogen-Activated Protein Kinase Activation in Lung Adenocarcinoma: A Comparative Study between Ever Smokers and Never Smokers. <i>Clinical Cancer Research</i> , 2008, 14, 4096-4102.	7.0	20
474	Could Rigorous Diagnosis and Management of Hypertension Reduce Cardiac Events in Patients With Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors?. <i>Journal of Clinical Oncology</i> , 2009, 27, 2567-2569.	1.6	20
475	Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 110-117.	0.4	20
476	Bortezomib for AL amyloidosis: moving forward. <i>Blood</i> , 2011, 118, 827-828.	1.4	20
477	Conservative Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients. <i>International Journal of Dentistry</i> , 2014, 2014, 1-7.	1.5	20
478	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. <i>HemaSphere</i> , 2019, 3, e300.	2.7	20
479	Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece. <i>Medicine (United States)</i> , 2020, 99, e23845.	1.0	20
480	One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone. <i>Blood</i> , 2018, 132, 156-156.	1.4	20
481	Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNOVATETM Study. <i>Blood</i> , 2018, 132, 149-149.	1.4	20
482	“The emerging role of capivasertib in breast cancer” <i>Breast</i> , 2022, 63, 157-167.	2.2	20
483	Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer: A Hellenic Cooperative Oncology Group (HeCOG) study. <i>European Journal of Cancer</i> , 2008, 44, 2169-2177.	2.8	19
484	Periodic Therapeutic Plasma Exchange in Patients With Moderate to Severe Chronic Myasthenia Gravis Non-Responsive to Immunosuppressive Agents: An Eight Year Follow-Up. <i>Therapeutic Apheresis and Dialysis</i> , 2009, 13, 174-178.	0.9	19
485	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. <i>Leukemia and Lymphoma</i> , 2015, 56, 1723-1726.	1.3	19
486	Treatment of relapsed urothelial bladder cancer with vinflunine. <i>Anti-Cancer Drugs</i> , 2016, 27, 48-53.	1.4	19

#	ARTICLE	IF	CITATIONS
487	Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. <i>Haematologica</i> , 2016, 101, 872-878.	3.5	19
488	Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). <i>Annals of Translational Medicine</i> , 2018, 6, 144-144.	1.7	19
489	Anti-BCMA antibodies in the future management of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 319-326.	2.4	19
490	Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. <i>Thrombosis and Haemostasis</i> , 2009, 101, 541-546.	3.4	19
491	Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNOVATETM Study. <i>Blood</i> , 2020, 136, 24-26.	1.4	19
492	Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in Stage III and IV ovarian carcinoma. <i>Cancer</i> , 2000, 89, 1547-1554.	4.1	18
493	Young Age Is Associated with Favorable Characteristics but Is Not an Independent Prognostic Factor in Patients with Epithelial Ovarian Cancer: A Single Institution Experience. <i>Oncology</i> , 2006, 70, 265-272.	1.9	18
494	Prognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine: A Single Institution Experience. <i>European Urology</i> , 2008, 53, 323-332.	1.9	18
495	The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma. <i>BMC Cancer</i> , 2014, 14, 149.	2.6	18
496	Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 3-11.	3.0	18
497	Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. <i>British Journal of Haematology</i> , 2022, 196, 356-359.	2.5	18
498	CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002. <i>Blood</i> , 2021, 138, 2731-2731.	1.4	18
499	Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma. <i>Radiology</i> , 2022, 304, 137-144.	7.3	18
500	Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation. <i>American Journal of Hematology</i> , 1992, 41, 40-44.	4.1	17
501	Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 43, 329-334.	0.8	17
502	Thalidomide in the treatment of multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 681-699.	1.7	17
503	Treatment of Waldenstrom's Macroglobulinemia. <i>Current Treatment Options in Oncology</i> , 2007, 8, 144-153.	3.0	17
504	Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer. <i>Hellenic Journal of Cardiology</i> , 2017, 58, 215-219.	1.0	17

#	ARTICLE	IF	CITATIONS
505	Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2304-2309.	1.3	17
506	Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. <i>Scientific Reports</i> , 2017, 7, 17802.	3.3	17
507	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. <i>Blood Advances</i> , 2019, 3, 4095-4103.	5.2	17
508	Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5449-5459.	5.2	17
509	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2020, 190, 346-357.	2.5	17
510	Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. <i>Leukemia</i> , 2020, 34, 3019-3027.	7.2	17
511	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1251-1255.	1.8	17
512	Trastuzumab administration during pregnancy: an update. <i>BMC Cancer</i> , 2021, 21, 463.	2.6	17
513	Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?. <i>American Journal of Hematology</i> , 2021, 96, E321-E324.	4.1	17
514	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. <i>HemaSphere</i> , 2022, 6, e677.	2.7	17
515	Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: Long term follow up and disease control after subsequent treatments. <i>Leukemia and Lymphoma</i> , 2007, 48, 754-758.	1.3	16
516	Clinical Characteristics and Outcome of Primary Systemic Light-Chain Amyloidosis in Greece. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 56-61.	0.4	16
517	Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2011, 86, 882-884.	4.1	16
518	Replication Protein A in Nonrare Ovarian Adenocarcinomas. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 319-327.	1.4	16
519	Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. <i>Cancer Treatment Reviews</i> , 2012, 38, 1012-1019.	7.7	16
520	Improved Survival Trends in Platinum-Resistant Patients with Advanced Ovarian, Fallopian or Peritoneal Cancer Treated with First-Line Paclitaxel/Platinum Chemotherapy: The Impact of Novel Agents. <i>Oncology</i> , 2013, 84, 158-165.	1.9	16
521	Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 335-340.	0.4	16
522	Neutrophil Gelatinase-Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 29-35.	0.4	16

#	ARTICLE	IF	CITATIONS
523	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the <scp>PANORAMA</scp> 1 trial. <i>British Journal of Haematology</i> , 2017, 179, 66-74.	2.5	16
524	Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2019, 184, 536-546.	2.5	16
525	Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis. <i>Blood Cancer Journal</i> , 2020, 10, 35.	6.2	16
526	Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 25.	6.2	16
527	Once-weekly (70 mg/m <sup>2</sup> ) vs twice-weekly (56 mg/m <sup>2</sup> ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION trials. <i>Cancer Medicine</i> , 2020, 9, 2989-2996.	2.8	16
528	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 708-718.	4.1	16
529	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. <i>Blood</i> , 2020, 136, 37-38.	1.4	16
530	Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070). <i>Blood</i> , 2015, 126, 26-26.	1.4	16
531	Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial. <i>Blood</i> , 2017, 130, 743-743.	1.4	16
532	Metabolic Disorders in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11430.	4.1	16
533	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. <i>Haematologica</i> , 2022, 107, 1397-1409.	3.5	16
534	How I treat relapsed multiple myeloma. <i>Blood</i> , 2022, 139, 2904-2917.	1.4	16
535	Breast cancer and second primary ovarian cancer in dermatomyositis. <i>Gynecologic Oncology</i> , 1991, 43, 286-290.	1.4	15
536	Ambulatory blood pressure monitoring in acute stroke. <i>Blood Pressure Monitoring</i> , 2013, 18, 94-100.	0.8	15
537	Meat, fish, dairy products and risk of hematological malignancies in adults – a systematic review and meta-analysis of prospective studies. <i>Leukemia and Lymphoma</i> , 2019, 60, 1978-1990.	1.3	15
538	Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2006.	3.7	15
539	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. <i>Blood Cancer Journal</i> , 2020, 10, 40.	6.2	15
540	Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. <i>British Journal of Haematology</i> , 2021, 193, 113-118.	2.5	15

#	ARTICLE	IF	CITATIONS
541	Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. <i>Leukemia</i> , 2021, 35, 1418-1427.	7.2	15
542	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. <i>Oncologist</i> , 2021, 26, 597-609.	3.7	15
543	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. <i>American Journal of Hematology</i> , 2021, 96, 1120-1130.	4.1	15
544	SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. <i>Breast</i> , 2021, 60, 58-61.	2.2	15
545	The Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma Who Receive Biphosphonates Depends on the Type of Biphosphonate.. <i>Blood</i> , 2005, 106, 637-637.	1.4	15
546	Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study. <i>Blood</i> , 2014, 124, 79-79.	1.4	15
547	Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial. <i>Blood</i> , 2015, 126, 730-730.	1.4	15
548	Pomalidomide (POM), bortezomib, and low-dose dexamethasone (Pvd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8001-8001.	1.6	15
549	Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG). <i>PLoS ONE</i> , 2013, 8, e70634.	2.5	15
550	Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study. <i>Frontiers in Endocrinology</i> , 2022, 13, 840668.	3.5	15
551	Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors. <i>Leukemia and Lymphoma</i> , 2004, 45, 2275-2279.	1.3	14
552	Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 161-167.	2.5	14
553	The role of the cell adhesion molecules (integrins / cadherins) in prostate cancer. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2011, 37, 302-306.	1.5	14
554	Managing renal complications in multiple myeloma. <i>Expert Review of Hematology</i> , 2016, 9, 839-850.	2.2	14
555	Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. <i>HemaSphere</i> , 2020, 4, e381.	2.7	14
556	Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. <i>Microorganisms</i> , 2021, 9, 546.	3.6	14
557	Subgroup Analysis of Patients with Biochemical or Symptomatic Relapse at the Time of Enrollment in the Endeavor Study. <i>Blood</i> , 2018, 132, 3243-3243.	1.4	14
558	Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study. <i>Blood</i> , 2012, 120, LBA-6-LBA-6.	1.4	14



#	ARTICLE	IF	CITATIONS
559	Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase II 2 trial. <i>Blood Cancer Journal</i> , 2022, 12, 9.	6.2	14
560	Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response. <i>Cells</i> , 2022, 11, 1241.	4.1	14
561	Cisplatin, Ifosfamide, Methotrexate and Vinblastine Combination Chemotherapy for Metastatic Urothelial Cancer. <i>Journal of Urology</i> , 1997, 158, 408-411.	0.4	13
562	Antimyosin Scintigraphy for Detection of Cardiac Amyloidosis. <i>American Journal of Cardiology</i> , 1997, 80, 963-965.	1.6	13
563	Familial female and male germ cell cancer. A new syndrome?. <i>Gynecologic Oncology</i> , 2005, 96, 254-255.	1.4	13
564	Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: Promising results in marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 68-74.	1.3	13
565	Characterization of haematological parameters with bortezomib+melphalan+prednisone versus melphalan+prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. <i>British Journal of Haematology</i> , 2011, 153, 212-221.	2.5	13
566	Alcohol intake, alcoholic beverage type and multiple myeloma risk: a meta-analysis of 26 observational studies. <i>Leukemia and Lymphoma</i> , 2015, 56, 1484-1501.	1.3	13
567	Emerging treatment approaches for myeloma-related bone disease. <i>Expert Review of Hematology</i> , 2017, 10, 217-228.	2.2	13
568	Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis. <i>Cancer Treatment Reviews</i> , 2019, 79, 101885.	7.7	13
569	Evaluating ibrutinib in the treatment of symptomatic Waldenström's macroglobulinemia. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 291-300.	1.7	13
570	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 93.	6.2	13
571	Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. <i>Blood Cancer Journal</i> , 2020, 10, 111.	6.2	13
572	Efficacy and safety of weekly carfilzomib (70 mg/m <sup>2</sup> ), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. <i>Leukemia and Lymphoma</i> , 2021, 62, 358-367.	1.3	13
573	Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. <i>British Journal of Haematology</i> , 2021, 194, 132-139.	2.5	13
574	Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. <i>The Hematology Journal</i> , 2003, 4, 110-115.	1.4	13
575	Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas. <i>Blood</i> , 2019, 134, 3140-3140.	1.4	13
576	DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 53-54.	1.4	13

#	ARTICLE	IF	CITATIONS
577	Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First-Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial. <i>Blood</i> , 2020, 136, 26-26.	1.4	13
578	A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial. <i>Blood</i> , 2015, 126, 4239-4239.	1.4	13
579	Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8018-8018.	1.6	13
580	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. <i>Annals of Translational Medicine</i> , 2018, 6, 143-143.	1.7	13
581	Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 460-473.	0.4	13
582	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13144.	4.1	13
583	Non-cryopreserved peripheral blood progenitor cells collected by a single very large-volume leukapheresis: A simplified and effective procedure for support of high-dose chemotherapy. <i>Journal of Clinical Apheresis</i> , 2000, 15, 236-241.	1.3	12
584	Primary Treatment of Low-grade Non-Hodgkin's Lymphoma with the Combination of Fludarabine and Mitoxantrone: A Phase II Study of the Hellenic Cooperative Oncology Group. <i>Leukemia and Lymphoma</i> , 2002, 43, 111-114.	1.3	12
585	Endovascular stenting for the management of port-a-cath associated superior vena cava syndrome. <i>Emergency Radiology</i> , 2009, 16, 143-146.	1.8	12
586	Rituximab-Based Treatments in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 59-61.	1.4	12
587	Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): A risk adapted protocol of the Hellenic Cooperative Oncology Group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 189-193.	1.6	12
588	Current treatment options and investigational drugs for Waldenström's Macroglobulinemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 197-205.	4.1	12
589	Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. <i>Trials. International Journal of Hematology</i> , 2019, 110, 466-473.	1.6	12
590	Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?. <i>Expert Review of Hematology</i> , 2019, 12, 651-663.	2.2	12
591	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. <i>Cancers</i> , 2020, 12, 2864.	3.7	12
592	Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5185.	4.1	12
593	Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations. <i>American Journal of Hematology</i> , 2020, 95, E148-E150.	4.1	12
594	SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. <i>Vaccines</i> , 2021, 9, 207.	4.4	12

#	ARTICLE	IF	CITATIONS
595	A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis. <i>Microorganisms</i> , 2021, 9, 806.	3.6	12
596	A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 3877.	3.7	12
597	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009701.	4.7	12
598	Diffusion-Weighted Imaging Improves Accuracy in the Diagnosis of MRI Patterns of Marrow Involvement in Newly Diagnosed Myeloma: Results of a Prospective Study in 99 Patients. <i>Blood</i> , 2015, 126, 4178-4178.	1.4	12
599	Distinct neutralization profile of spike variants by antibodies induced upon <sc>SARS-CoV-2</sc> infection or vaccination. <i>American Journal of Hematology</i> , 2022, 97, E3.	4.1	12
600	Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival. <i>Frontiers in Oncology</i> , 2022, 12, 847917.	2.8	12
601	Physical Exercise Restrains Cancer Progression through Muscle-Derived Factors. <i>Cancers</i> , 2022, 14, 1892.	3.7	12
602	High Dose Therapy with Autologous Stem Cell Transplantation for Solitary Bone Plasmacytoma Complicated by Local Relapse or Isolated Distant Recurrence. <i>Leukemia and Lymphoma</i> , 2003, 44, 153-155.	1.3	11
603	Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. <i>BMC Cancer</i> , 2006, 6, 228.	2.6	11
604	Evaluation of the Prognostic Value of Cellular Inhibitor of Apoptosis Protein in Epithelial Ovarian Cancer Using Automated Quantitative Protein Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1179-1183.	2.5	11
605	High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. <i>British Journal of Haematology</i> , 2010, 150, 587-591.	2.5	11
606	Prevention and Treatment of Myeloma Bone Disease. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 249-257.	2.3	11
607	Proteasome Inhibitors in Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 829-840.	2.2	11
608	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 163-171.	1.3	11
609	Updates on thrombotic events associated with multiple myeloma. <i>Expert Review of Hematology</i> , 2019, 12, 355-365.	2.2	11
610	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. <i>European Journal of Haematology</i> , 2019, 102, 494-503.	2.2	11
611	Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. <i>American Journal of Hematology</i> , 2019, 94, E146-E149.	4.1	11
612	Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. <i>HemaSphere</i> , 2020, 4, e433.	2.7	11

#	ARTICLE	IF	CITATIONS
613	Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 103-110.	3.0	11
614	Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1850-1859.	1.3	11
615	Current and novel BTK inhibitors in Waldenström's macroglobulinemia. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198958.	2.5	11
616	The relationship between cardiac injury, inflammation and coagulation in predicting COVID-19 outcome. <i>Scientific Reports</i> , 2021, 11, 6515.	3.3	11
617	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 59.	17.0	11
618	Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2021, 39, 8017-8017.	1.6	11
619	Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients. <i>Cancers</i> , 2021, 13, 2452.	3.7	11
620	Real-World Treatment of Patients With Relapsed/Refractory Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 379-385.	0.4	11
621	Novel Nested-Seq Approach for SARS-CoV-2 Real-Time Epidemiology and In-Depth Mutational Profiling in Wastewater. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8498.	4.1	11
622	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2014, 124, 35-35.	1.4	11
623	Final Analysis of Overall Survival from the First Trial. <i>Blood</i> , 2016, 128, 241-241.	1.4	11
624	Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working Group. <i>Blood</i> , 2016, 128, 4468-4468.	1.4	11
625	miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. <i>British Journal of Cancer</i> , 2022, 126, 79-90.	6.4	11
626	Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. <i>Nature Communications</i> , 2022, 13, .	12.8	11
627	Myeloablative therapy for primary resistant multiple myeloma. <i>Stem Cells</i> , 1996, 13, 118-121.	3.2	10
628	Bcl-2 protein and DNA ploidy in renal cell carcinoma: Do they affect patient prognosis?. <i>International Journal of Urology</i> , 2005, 12, 563-569.	1.0	10
629	Extranodal non-Hodgkin's lymphoma presenting as an abdominal wall mass. A case report and review of the literature. <i>Leukemia and Lymphoma</i> , 2006, 47, 329-332.	1.3	10
630	Avascular Osteonecrosis of the Jaw as a Side Effect of Bisphosphonate Treatment. <i>Onkologie</i> , 2010, 33, 288-289.	0.8	10

#	ARTICLE	IF	CITATIONS
631	Leukocytoclastic Vasculitis after Long-Term Treatment with Sunitinib: A Case Report. <i>Case Reports in Oncology</i> , 2011, 4, 385-391.	0.7	10
632	Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 842-853.	2.4	10
633	Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. <i>Medical Oncology</i> , 2012, 29, 750-754.	2.5	10
634	Association of VEGF-A Splice Variant mRNA Expression With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 330-338.	2.4	10
635	Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance. <i>Leukemia and Lymphoma</i> , 2016, 57, 1382-1388.	1.3	10
636	Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 663-677.	2.0	10
637	Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function. <i>Clinical Pharmacology: Advances and Applications</i> , 2017, Volume 9, 133-145.	1.2	10
638	How We Manage Patients with Plasmacytomas. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 227-235.	2.3	10
639	Management of multiple myeloma bone disease: impact of treatment on renal function. <i>Expert Review of Hematology</i> , 2018, 11, 881-888.	2.2	10
640	Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 2-10.	2.0	10
641	Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide. <i>Cancers</i> , 2019, 11, 1764.	3.7	10
642	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. <i>International Journal of Cancer</i> , 2019, 145, 559-568.	5.1	10
643	Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 57-62.	0.4	10
644	Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial. <i>European Journal of Haematology</i> , 2020, 104, 443-458.	2.2	10
645	Long-Term Neurodevelopmental Outcome of Children after in Utero Exposure to Chemotherapy. <i>Cancers</i> , 2020, 12, 3623.	3.7	10
646	Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 361-367.	0.4	10
647	MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment. <i>Cancers</i> , 2021, 13, 4114.	3.7	10
648	Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group. <i>Journal of Clinical Medicine</i> , 2021, 10, 3940.	2.4	10

#	ARTICLE	IF	CITATIONS
649	Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses. <i>Journal of Clinical Medicine</i> , 2021, 10, 4179.	2.4	10
650	Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: <scp>ICARIAâ€œMM</scp> subgroup analysis. <i>American Journal of Hematology</i> , 2021, 96, E423-E427.	4.1	10
651	Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 408-408.	1.4	10
652	Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8040-8040.	1.6	10
653	Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis. <i>PLoS ONE</i> , 2015, 10, e0116966.	2.5	10
654	Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent. <i>Oncotarget</i> , 2018, 9, 17797-17809.	1.8	10
655	The extended 4-year follow-up results of the ELOQUENT-2 trial. <i>Oncotarget</i> , 2019, 10, 82-83.	1.8	10
656	Pembrolizumab in endometrial cancer: Where we stand now (Review). <i>Oncology Letters</i> , 2021, 22, 821.	1.8	10
657	Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. <i>Vaccines</i> , 2021, 9, 1148.	4.4	10
658	Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection. <i>Frontiers in Immunology</i> , 2021, 12, 746203.	4.8	10
659	Determination of <i>MYD88L265P</i> mutation fraction in IgM monoclonal gammopathies. <i>Blood Advances</i> , 2022, 6, 189-199.	5.2	10
660	Third dose of the <scp>BNT162b2</scp> vaccine results in very high levels of neutralizing antibodies against <scp>SARSâ€œCoV</scp>â€œ2: Results of a prospective study in 150 health professionals in Greece. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	10
661	Chromosome 1q21 aberrations identify ultra <scp>highâ€œrisk</scp> myeloma with prognostic and clinical implications. <i>American Journal of Hematology</i> , 2022, 97, 1142-1149.	4.1	10
662	A Phase III Study of 5-Fluorouracil Versus 5-Fluorouracil Plus Interferon Alpha 2b Versus 5-Fluorouracil Plus Leucovorin in Patients With Advanced Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 23-30.	1.3	9
663	Non-Hodgkin's Lymphoma of the Renal Pelvis. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 404-406.	1.4	9
664	Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma. <i>Cancer Treatment Reviews</i> , 2009, 35, 738-743.	7.7	9
665	Prechemotherapy Serum Levels of CD105, Transforming Growth Factor Î²2, and Vascular Endothelial Growth Factor Are Associated With Prognosis in Patients With Advanced Epithelial Ovarian Cancer Treated With Cytoreductive Surgery and Platinum-Based Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 248-254.	2.5	9
666	Adjusting for Patient Crossover in Clinical Trials Using External Data: A Case Study of Lenalidomide for Advanced Multiple Myeloma. <i>Value in Health</i> , 2011, 14, 672-678.	0.3	9

#	ARTICLE	IF	CITATIONS
667	An update on the use of lenalidomide for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2015, 16, 1865-1877.	1.8	9
668	Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). Leukemia and Lymphoma, 2016, 57, 2839-2847.	1.3	9
669	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. Leukemia and Lymphoma, 2017, 58, 1506-1508.	1.3	9
670	Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. Annals of Hematology, 2019, 98, 1427-1434.	1.8	9
671	Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature. Clinical Genitourinary Cancer, 2019, 17, e360-e364.	1.9	9
672	Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. Leukemia and Lymphoma, 2019, 60, 619-628.	1.3	9
673	The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. Leukemia and Lymphoma, 2020, 61, 680-690.	1.3	9
674	Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. Annals of Hematology, 2020, 99, 1257-1264.	1.8	9
675	Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group. American Journal of Hematology, 2020, 95, 465-471.	4.1	9
676	Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e905-e909.	0.4	9
677	Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. Cancers, 2021, 13, 1257.	3.7	9
678	Germline mutations in a clinic-based series of pregnancy associated breast cancer patients. BMC Cancer, 2021, 21, 572.	2.6	9
679	Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. Blood, 2018, 132, 301-301.	1.4	9
680	How I treat elderly patients with plasma cell dyscrasias. Aging, 2018, 10, 4248-4268.	3.1	9
681	Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials. Blood, 2018, 132, 1963-1963.	1.4	9
682	SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition. Cancers, 2022, 14, 2796.	3.7	9
683	Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study.. Journal of Clinical Oncology, 2022, 40, 7566-7566.	1.6	9
684	An effective acute graft-vs.-host disease prophylaxis with minidose methotrexate, cyclosporine, and single-dose methylprednisolone. American Journal of Hematology, 1991, 38, 288-292.	4.1	8

#	ARTICLE	IF	CITATIONS
685	VAD-Cyclosporine Therapy for VAD-Resistant Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1995, 19, 159-163.	1.3	8
686	Expansion of CD8+ T cells that express low levels of the B cell-specific molecule CD20 in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2003, 120, 478-481.	2.5	8
687	Management of Relapsed and Relapsed Refractory Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1175-1215.	2.2	8
688	Management of advanced bladder cancer in patients with impaired renal function. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 931-939.	2.4	8
689	Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy. <i>European Journal of Haematology</i> , 2011, 87, 323-329.	2.2	8
690	The repair of melphalan-induced DNA adducts in the transcribed strand of active genes is subject to a strong polarity effect. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2011, 714, 78-87.	1.0	8
691	Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents. <i>American Journal of Hematology</i> , 2012, 87, 734-736.	4.1	8
692	<i>TLR4</i> polymorphisms are associated with progression and survival of patients with symptomatic myeloma. <i>British Journal of Haematology</i> , 2016, 172, 44-47.	2.5	8
693	Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG). <i>Clinical Genitourinary Cancer</i> , 2016, 14, e153-e159.	1.9	8
694	Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 921-928.	2.4	8
695	A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options. <i>BMC Medical Genetics</i> , 2019, 20, 23.	2.1	8
696	Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?. <i>ESMO Open</i> , 2019, 4, e000479.	4.5	8
697	Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy. <i>Medicine (United States)</i> , 2019, 98, e018021.	1.0	8
698	Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes: a Hellenic Cooperative Oncology Group (HeCOG) Trial. <i>British Journal of Cancer</i> , 2020, 123, 355-361.	6.4	8
699	Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation. <i>American Journal of Roentgenology</i> , 2021, 216, 742-751.	2.2	8
700	The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. <i>Vaccines</i> , 2021, 9, 422.	4.4	8
701	Molecular Epidemiology of SARS-CoV-2 in Greece Reveals Low Rates of Onward Virus Transmission after Lifting of Travel Restrictions Based on Risk Assessment during Summer 2020. <i>MSphere</i> , 2021, 6, e0018021.	2.9	8
702	Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. <i>Cancers</i> , 2021, 13, 4047.	3.7	8



#	ARTICLE	IF	CITATIONS
703	Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 259-266.	3.0	8
704	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021, 21, 993.	2.6	8
705	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. <i>European Journal of Haematology</i> , 2022, 108, 73-83.	2.2	8
706	The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1 $\beta$ and Angiogenic Cytokines. <i>Blood</i> , 2006, 108, 3541-3541.	1.4	8
707	Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866). <i>Blood</i> , 2015, 126, 30-30.	1.4	8
708	Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). <i>Blood</i> , 2015, 126, 731-731.	1.4	8
709	Health Related Quality of Life Results from the Open-Label, Randomized, Phase III Endeavor Trial Evaluating Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 3309-3309.	1.4	8
710	Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO). <i>Journal of Clinical Oncology</i> , 2018, 36, TPS8059-TPS8059.	1.6	8
711	Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS8062-TPS8062.	1.6	8
712	Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1603-1603.	1.7	8
713	Elucidating Carfilzomib-Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10956.	4.1	8
714	Preliminary Clinical Response Data from a Phase 1b Study of Mavoxifafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations. <i>Blood</i> , 2021, 138, 1362-1362.	1.4	8
715	tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature. <i>Biomedicines</i> , 2021, 9, 1811.	3.2	8
716	The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells. <i>Biomedicines</i> , 2022, 10, 209.	3.2	8
717	Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group. <i>Anticancer Research</i> , 2014, 34, 5649-55.	1.1	8
718	Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210900.	2.5	8
719	Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	8
720	Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation. <i>American Journal of Hematology</i> , 1994, 46, 82-86.	4.1	7

#	ARTICLE	IF	CITATIONS
721	Primary Mediastinal Large B-Cell Lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 312-316.	1.3	7
722	Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?. Leukemia and Lymphoma, 2006, 47, 2271-2272.	1.3	7
723	Laparoscopy in the evaluation of women with unexplained ascites: An invaluable diagnostic tool. Journal of Minimally Invasive Gynecology, 2007, 14, 43-48.	0.6	7
724	Therapeutic Plasma Exchange Combined With Immunomodulating Agents in Secondary Progressive Multiple Sclerosis Patients. Therapeutic Apheresis and Dialysis, 2008, 12, 105-108.	0.9	7
725	Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer. OncoTargets and Therapy, 2014, 7, 1837.	2.0	7
726	Hematologic Response and Stabilization of Renal Function in a Patient With Light Chain Deposition Disease After Lenalidomide Treatment: A Novel Therapeutic Approach?. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e179-e181.	0.4	7
727	Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. Annals of Hematology, 2017, 96, 1707-1714.	1.8	7
728	Ibrutinib and Rituximab in Waldenström's Macroglobulinemia. New England Journal of Medicine, 2018, 379, 1973-1976.	27.0	7
729	Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19. Gynecologic Oncology Reports, 2020, 33, 100615.	0.6	7
730	Multiple myeloma: Current and future management in the aging population. Maturitas, 2020, 138, 8-13.	2.4	7
731	Exercise-Induced Changes in Tumor Growth via Tumor Immunity. Sports, 2021, 9, 46.	1.7	7
732	Cardiovascular toxicity of breast cancer treatment: an update. Cancer Chemotherapy and Pharmacology, 2021, 88, 15-24.	2.3	7
733	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. American Journal of Hematology, 2021, 96, E383-E386.	4.1	7
734	Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. HemaSphere, 2021, 5, e614.	2.7	7
735	Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review. Cancers, 2021, 13, 465.	3.7	7
736	Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenström's Macroglobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial. Blood, 2019, 134, 344-344.	1.4	7
737	Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 INNOVATE™ Trial. Blood, 2020, 136, 38-39.	1.4	7
738	Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone.. Blood, 2009, 114, 2879-2879.	1.4	7

#	ARTICLE	IF	CITATIONS
739	Lenalidomide plus Dexamethasone Has Similar Tolerability and Efficacy in Treatment of Relapsed/Refractory Multiple Myeloma Patients with or without History of Neuropathy.. Blood, 2009, 114, 3873-3873.	1.4	7
740	Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI).. Journal of Clinical Oncology, 2013, 31, 8527-8527.	1.6	7
741	Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma. Medical Science Monitor, 2013, 19, 1188-1194.	1.1	7
742	Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study. Oncotarget, 2018, 9, 36906-36913.	1.8	7
743	Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy. Clinical Nephrology, 2016, 85 (2016), 44-54.	0.7	7
744	Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers. Vaccines, 2021, 9, 1179.	4.4	7
745	Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study. Blood, 2020, 136, 48-49.	1.4	7
746	Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. Biomedicines, 2022, 10, 204.	3.2	7
747	Non-secretory myeloma: one, two, or more entities?. Oncology, 2013, 27, 930-2.	0.5	7
748	The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis. Insights Into Imaging, 2022, 13, 55.	3.4	7
749	Efficacy and tolerability of onceâ€¦weekly selinexor, bortezomib, and dexamethasone in comparison with standard twiceâ€¦weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study. American Journal of Hematology, 2022, 97, .	4.1	7
750	Concurrent development of testicular seminoma and choriocarcinoma of the superior mediastinum, presented as cervical mass: a case report and implications about pathogenesis of germ-cell tumours. BMC Clinical Pathology, 2006, 6, 8.	1.8	6
751	Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma. Nature Clinical Practice Oncology, 2008, 5, 690-691.	4.3	6
752	First-line bortezomib benefits patients with multiple myeloma. Nature Reviews Clinical Oncology, 2009, 6, 683-685.	27.6	6
753	Proteasome Inhibitor Therapy for WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 235-237.	0.4	6
754	Solitary bone plasmacytomas need to flow. Blood, 2014, 124, 1209-1210.	1.4	6
755	Outcome of patients with nonmetastatic muscleâ€¦invasive bladder cancer not undergoing cystectomy after treatment with noncisplatinâ€¦based chemotherapy and/or radiotherapy: a retrospective analysis. Cancer Medicine, 2016, 5, 1098-1107.	2.8	6
756	Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. Hematological Oncology, 2017, 35, 734-740.	1.7	6

#	ARTICLE	IF	CITATIONS
757	Brain Oscillations Elicited by the Cold Pressor Test: A Putative Index of Untreated Essential Hypertension. <i>International Journal of Hypertension</i> , 2017, 2017, 1-17.	1.3	6
758	Carfilzomib+dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. <i>Leukemia and Lymphoma</i> , 2018, 59, 1364-1374.	1.3	6
759	Rare manifestations of extramedullary myeloma: testicular plasmacytomas. <i>Leukemia and Lymphoma</i> , 2018, 59, 2002-2004.	1.3	6
760	Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S249-S250.	0.4	6
761	Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven Process. <i>TH Open</i> , 2019, 03, e340-e347.	1.4	6
762	Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials. <i>Leukemia and Lymphoma</i> , 2020, 61, 37-46.	1.3	6
763	Clinical Perspectives of ERCC1 in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8829.	4.1	6
764	Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 638895.	2.4	6
765	Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review. <i>Breast Care</i> , 2022, 17, 63-70.	1.4	6
766	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. <i>Future Oncology</i> , 2021, 17, 4797-4812.	2.4	6
767	Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study. <i>Blood</i> , 2019, 134, 1850-1850.	1.4	6
768	Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis. <i>Blood</i> , 2015, 126, 374-374.	1.4	6
769	How I treat rituximab refractory patients with WM. <i>Oncotarget</i> , 2018, 9, 36824-36825.	1.8	6
770	Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study. <i>Cancers</i> , 2021, 13, 5057.	3.7	6
771	Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. <i>Blood</i> , 2021, 138, 153-153.	1.4	6
772	Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial. <i>Blood</i> , 2020, 136, 30-31.	1.4	6
773	Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial. <i>American Journal of Hematology</i> , 2022, 97, 481-490.	4.1	6
774	Plasmablastic lymphoma of the breast in an immunocompetent patient: long-lasting complete response induced by chemotherapy and autologous stem cell transplantation. <i>Anticancer Research</i> , 2014, 34, 5111-5.	1.1	6

#	ARTICLE	IF	CITATIONS
775	Immune response and adverse events after vaccination against <sc>SARS-CoV-2</sc> in adult patients with transfusion-dependent thalassaemia. <i>British Journal of Haematology</i> , 2022, 197, 576-579.	2.5	6
776	Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: <sc>IKEMA</sc> subgroup analysis. <i>American Journal of Hematology</i> , 2023, 98, .	4.1	6
777	Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study &œREBUILD&œ. <i>Cancers</i> , 2022, 14, 2768.	3.7	6
778	Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals. <i>HemaSphere</i> , 2022, 6, e747.	2.7	6
779	Intensive Sequential Therapy for VAD-Resistant Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1994, 13, 479-484.	1.3	5
780	Late relapse of nonseminomatous germ cell tumor of the testis: Successful treatment with salvage chemotherapy alone. <i>Urology</i> , 1997, 49, 469-470.	1.0	5
781	Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). <i>Anti-Cancer Drugs</i> , 2004, 15, 479-487.	1.4	5
782	Two Cycles of Etoposide/Cisplatin Cured All Patients with Stage I Testicular Seminoma: Risk-Adapted Protocol of the Hellenic Cooperative Oncology Group. <i>Urology</i> , 2007, 70, 1179-1183.	1.0	5
783	Emerging drugs for Waldenstr&œm's macroglobulinemia. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 45-57.	2.4	5
784	When a little aspirin may be enough. <i>Blood</i> , 2012, 119, 905-906.	1.4	5
785	Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?. <i>OncoTargets and Therapy</i> , 2015, 8, 1843.	2.0	5
786	Current therapy guidelines for Waldenstrom's macroglobulinaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 194-205.	1.7	5
787	Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG). <i>World Journal of Urology</i> , 2016, 34, 853-857.	2.2	5
788	Disease control should be the goal of therapy for WM patients. <i>Blood Advances</i> , 2017, 1, 2483-2485.	5.2	5
789	Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenstr&œm Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 431-437.	0.4	5
790	Cardiac arrest and drug-related cardiac toxicity in the Covid-19 era. <i>Epidemiology, pathophysiology and management. Food and Chemical Toxicology</i> , 2020, 145, 111742.	3.6	5
791	Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2020, 157, 599-605.	1.4	5
792	Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma. <i>Viruses</i> , 2021, 13, 1844.	3.3	5

#	ARTICLE	IF	CITATIONS
793	Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Results of the Phase 3 Study Endeavor (NCT01568866) According to Age Subgroup. Blood, 2015, 126, 1844-1844.	1.4	5
794	Daratumumab plus CyBORd for patients with newly diagnosed light chain (AL) amyloidosis. Therapeutic Advances in Hematology, 2021, 12, 204062072110583.	2.5	5
795	Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy. American Journal of Hematology, 2022, 97, E27.	4.1	5
796	Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Blood, 2021, 138, 3886-3886.	1.4	5
797	Complications and supportive therapy of multiple myeloma. Best Practice and Research: Clinical Haematology, 1995, 8, 845-852.	1.1	4
798	Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein. Annals of Hematology, 2004, 83, 658-60.	1.8	4
799	How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide. Leukemia and Lymphoma, 2007, 48, 2295-2297.	1.3	4
800	Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer. International Journal of Cardiology, 2012, 154, 341-344.	1.7	4
801	The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2014, 55, 11-18.	1.3	4
802	Appraising myc involvement in high risk myeloma. Leukemia and Lymphoma, 2015, 56, 551-552.	1.3	4
803	Carfilzomib versus bortezomib for relapsed or refractory myeloma – Authors' reply. Lancet Oncology, The, 2016, 17, e126.	10.7	4
804	Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Expert Opinion on Drug Safety, 2017, 16, 1-9.	2.4	4
805	When to recommend a second autograft in patients with relapsed myeloma?. Leukemia and Lymphoma, 2017, 58, 781-787.	1.3	4
806	Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2018, 59, 983-987.	1.3	4
807	Nonlethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells. Journal of Cellular and Molecular Medicine, 2019, 23, 8010-8018.	3.6	4
808	The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. International Journal of Clinical Oncology, 2019, 24, 411-419.	2.2	4
809	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Annals of Hematology, 2020, 99, 1793-1804.	1.8	4
810	The current role of BTK inhibitors in the treatment of Waldenström's Macroglobulinemia. Expert Review of Anticancer Therapy, 2020, 20, 663-674.	2.4	4

#	ARTICLE	IF	CITATIONS
811	Cost-effectiveness of once weekly carfilzomib 70 mg/m <sup>2</sup> plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States. <i>Expert Review of Hematology</i> , 2020, 13, 687-696.	2.2	4
812	Ibrutinib plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 987-995.	2.4	4
813	Full Dose of Lenalidomide for 12 Months Followed by a Lower Maintenance Dose Improves Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2009, 114, 2874-2874.	1.4	4
814	Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes. <i>Blood</i> , 2014, 124, 306-306.	1.4	4
815	Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88 <sup>WT</sup> ) Waldenström macroglobulinemia (WM). <i>Journal of Clinical Oncology</i> , 2020, 38, e20056-e20056.	1.6	4
816	Efficacy of methotrexate/vinblastine/doxorubicin/cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis. <i>Open Access Journal of Urology</i> , 2010, 2, 193.	0.3	4
817	Disease-Associated Changes In The Repair Efficiency Of Double Strand Breaks Affect Melphalan Sensitivity Of The Bone Marrow Plasma Cells and Correlate With The Clinical Outcome Of Anti-Myeloma Therapy. <i>Blood</i> , 2013, 122, 3723-3723.	1.4	4
818	Genomic Predictors of Progression-Free Survival Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Carfilzomib and Dexamethasone or Bortezomib and Dexamethasone in the Phase 3 Endeavor Trial. <i>Blood</i> , 2017, 130, 839-839.	1.4	4
819	IMiDs for myeloma induced renal impairment. <i>Oncotarget</i> , 2018, 9, 35476-35477.	1.8	4
820	Nonselective proteasome inhibitors in multiple myeloma and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 335-347.	1.8	4
821	A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2021, 138, 2736-2736.	1.4	4
822	The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents. <i>Blood</i> , 2020, 136, 21-21.	1.4	4
823	The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 797505.	2.8	4
824	Persisting Endothelial Cell Activation and Hypercoagulability after COVID-19 Recovery: The Prospective Observational ROADMAP-Post COVID-19 Study. <i>Hemato</i> , 2022, 3, 111-121.	0.6	4
825	Characterizing Kinetics and Avidity of SARS-CoV-2 Antibody Responses in COVID-19 Greek Patients. <i>Viruses</i> , 2022, 14, 758.	3.3	4
826	Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls. <i>Journal of Clinical Medicine</i> , 2022, 11, 3355.	2.4	4
827	Primary treatment with 2-chlorodeoxyadenosine of low grade lymphomas that produce igg or IgA immunoglobulin. <i>American Journal of Hematology</i> , 1993, 43, 326-327.	4.1	3
828	Advances in the treatment of multiple myeloma. <i>European Journal of Cancer</i> , 2011, 47, S306-S308.	2.8	3

#	ARTICLE	IF	CITATIONS
829	Metachronous appearance of second malignancies in medullary thyroid carcinoma (MTC) patients: a diagnostic challenge and brief review of the literature. <i>Endocrine</i> , 2013, 44, 610-615.	2.3	3
830	Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1776-1780.	1.3	3
831	Daratumumab combinations: what can we learn?. <i>Blood</i> , 2017, 130, 957-958.	1.4	3
832	Denosumab for myeloma bone disease: ready for prime time?. <i>Lancet Oncology</i> , The, 2018, 19, 277-278.	10.7	3
833	Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 52-53.	3.0	3
834	A matching-adjusted indirect treatment comparison (MAIC) of daratumumabâ€“bortezomibâ€“melphalanâ€“prednisone (D-VMP) versus lenalidomideâ€“dexamethasone continuous (Rd continuous), lenalidomideâ€“dexamethasone 18 months (Rd 18), and melphalanâ€“prednisoneâ€“thalidomide (MPT). <i>Leukemia and Lymphoma</i> , 2020, 61, 714-720.	1.3	3
835	Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause. <i>Leukemia and Lymphoma</i> , 2020, 61, 3247-3250.	1.3	3
836	Emerging drugs for the treatment of WaldenstrÃ¶m macroglobulinemia. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 433-444.	2.4	3
837	Supportive medication in cancer during pregnancy. <i>BMC Pregnancy and Childbirth</i> , 2020, 20, 747.	2.4	3
838	Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e457-e472.	1.9	3
839	Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. <i>Cancers</i> , 2021, 13, 763.	3.7	3
840	Paraneoplastic cerebellar degeneration in platinum-responsive endometrial cancer: A case report and review of literature. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100826.	0.6	3
841	Carfilzomib-Associated Renal Toxicity Is Common and Unpredictable: An Analysis of 114 Patients. <i>Blood</i> , 2018, 132, 1966-1966.	1.4	3
842	Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study. <i>Blood</i> , 2020, 136, 35-36.	1.4	3
843	Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study. <i>Blood</i> , 2020, 136, 4-6.	1.4	3
844	Decreased Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZA) after Application of Preventive Measures.. <i>Blood</i> , 2007, 110, 3609-3609.	1.4	3
845	Bortezomib Plus Melphalanâ€“Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalanâ€“Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.. <i>Blood</i> , 2009, 114, 3859-3859.	1.4	3
846	Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy. <i>Blood</i> , 2014, 124, 4738-4738.	1.4	3



#	ARTICLE	IF	CITATIONS
847	Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study. <i>Blood</i> , 2014, 124, 4742-4742.	1.4	3
848	Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment. <i>Blood</i> , 2015, 126, 3031-3031.	1.4	3
849	Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. <i>Blood</i> , 2015, 126, 4201-4201.	1.4	3
850	An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2015, 126, 4225-4225.	1.4	3
851	Melflufen for the treatment of multiple myeloma. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 371-382.	3.1	3
852	Very Late Relapse of Hodgkin's Disease After 24 Years of Complete Remission. <i>Leukemia and Lymphoma</i> , 1997, 28, 215-217.	1.3	2
853	Sequential Administration of Doxorubicin and Paclitaxel Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil Combination (CMF) in Women with Metastatic Breast Cancer. <i>Oncology</i> , 1998, 55, 533-537.	1.9	2
854	Neoadjuvant chemotherapy in invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 993-1000.	2.4	2
855	Biweekly Doxorubicin/Ketoconazole as Second-Line Treatment in Docetaxel-Resistant, Hormone-Refractory Prostate Cancer. <i>Urology</i> , 2008, 71, 1181-1185.	1.0	2
856	High dose therapy for light chain amyloidosis: Can we reduce treatment related mortality further?. <i>Leukemia and Lymphoma</i> , 2008, 49, 4-5.	1.3	2
857	Relapse of Ovarian Cancer With Bone Marrow Infiltration and Concurrent Emergence of Therapy-Related Acute Myeloid Leukemia: A Case Report. <i>Journal of Clinical Oncology</i> , 2011, 29, e295-e296.	1.6	2
858	Reply to C.A. Hutchison et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e314-e314.	1.6	2
859	Ambulatory blood pressure monitoring in acute stroke. <i>Blood Pressure Monitoring</i> , 2012, 17, 220-221.	0.8	2
860	VWF, WM, and angiogenesis: is there a link?. <i>Blood</i> , 2012, 120, 3163-3164.	1.4	2
861	Evolving Chemotherapy Options for the Treatment of Myeloma Kidney: A 40-Year Perspective. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 312-323.	1.4	2
862	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma. , 0, , 121-133.		2
863	Less strength and more fractures for MGUS bones. <i>Blood</i> , 2014, 123, 603-604.	1.4	2
864	Carfilzomib for treating myeloma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 989-999.	0.8	2

#	ARTICLE	IF	CITATIONS
865	Gefitinib: an "orphan" drug for non-small cell lung cancer. Expert Opinion on Orphan Drugs, 2017, 5, 899-906.	0.8	2
866	Carfilzomib for relapsed or refractory multiple myeloma " Authors' reply. Lancet Oncology, The, 2018, 19, e2.	10.7	2
867	Managing myeloma with limited resources in the era of novel drugs. Leukemia and Lymphoma, 2018, 59, 2269-2270.	1.3	2
868	Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 23-28.	0.4	2
869	&lt;p&gt;Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?&lt;/p&gt;. Therapeutics and Clinical Risk Management, 2020, Volume 16, 141-146.	2.0	2
870	Screening for Gaucher disease among patients with plasma cell dyscrasias. Leukemia and Lymphoma, 2021, 62, 761-763.	1.3	2
871	Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting. Current Oncology, 2021, 28, 1143-1152.	2.2	2
872	Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.. Journal of Clinical Oncology, 2021, 39, 8024-8024.	1.6	2
873	Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.. Journal of Clinical Oncology, 2021, 39, 8019-8019.	1.6	2
874	Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.. Journal of Clinical Oncology, 2021, 39, 8020-8020.	1.6	2
875	ASSOCIATION OF -308G/A, -238G/A TNF- $\pm$ POLYMORPHISMS WITH MULTIPLE MYELOMA RISK AND SURVIVAL: A SYSTEMATIC REVIEW AND META-ANALYSIS.. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	2
876	Utilization and tolerance of beta-blockers among patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 31-37.	3.0	2
877	Deep Vein Thrombosis in Myeloma: Estimate of Prevalence and Recommendations for Therapy Based upon a Survey of Members of the International Myeloma Working Group (IMWG).. Blood, 2006, 108, 3571-3571.	1.4	2
878	Treatment of Patients with Multiple Myeloma Complicated by Renal Failure with Bortezomib - Based Regimens.. Blood, 2007, 110, 2739-2739.	1.4	2
879	The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.. Blood, 2007, 110, 3596-3596.	1.4	2
880	Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenström's Macroglobulinemia. Blood, 2013, 122, 1860-1860.	1.4	2
881	Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial. Blood, 2013, 122, 2939-2939.	1.4	2
882	MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (&gt; 65 Years of Age). Blood, 2013, 122, 3198-3198.	1.4	2

#	ARTICLE	IF	CITATIONS
883	Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 686-686.	1.4	2
884	The State of Chromatin Condensation, the Expression of Genes Involved in DNA Damage Response and the DNA Repair Capacity Affect the Drug Sensitivity of PBMCs of Myeloma Patients Treated with Melphalan. <i>Blood</i> , 2015, 126, 3628-3628.	1.4	2
885	MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8510-8510.	1.6	2
886	The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in refractory or relapsed and refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8625-TPS8625.	1.6	2
887	Evaluation of the effect of CXCL13 mRNA expression in early breast cancer outcome: A confirmatory study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24286-e24286.	1.6	2
888	A phase 3 randomized, controlled, open-label study of selinexor, bortezomib, and dexamethasone (SVD) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS8056-TPS8056.	1.6	2
889	Pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20562-e20562.	1.6	2
890	Clinical biomarkers directing the management of patients with colon and lung cancer (beyond) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46	0.2	2
891	BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients. <i>Current Oncology</i> , 2021, 28, 4446-4456.	2.2	2
892	Future Developments in the Treatment of AL Amyloidosis. <i>Hemato</i> , 2022, 3, 131-152.	0.6	2
893	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210884.	2.5	2
894	Gender differences in COVID-19. <i>Maturitas</i> , 2022, 161, 72-73.	2.4	2
895	Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. <i>In Vivo</i> , 2022, 36, 1302-1315.	1.3	2
896	Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 3088.	2.4	2
897	Treatment of AL amyloidosis with high dose therapy and autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2006, 47, 963-964.	1.3	1
898	Multiple Myeloma in the Era of Novel Agents. <i>Seminars in Hematology</i> , 2009, 46, 107-109.	3.4	1
899	Prognostication of the High-Risk WM Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 127-129.	0.4	1
900	A Risk-Adapted Strategy of Adjuvant Paclitaxel/Carboplatin in Early-Stage Ovarian Cancer: Time-Dependent Effect of 4 versus 6 Cycles on Outcome. <i>Oncology</i> , 2011, 81, 365-371.	1.9	1

#	ARTICLE	IF	CITATIONS
901	Reply to S. Girnius et al. Journal of Clinical Oncology, 2013, 31, 2750-2751.	1.6	1
902	Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma. JAMA Oncology, 2016, 2, 1261.	7.1	1
903	Prognosis and risk assessment in AL amyloidosis - There and back again. British Journal of Haematology, 2017, 177, 343-345.	2.5	1
904	Treatment Recommendations in Waldenström Macroglobulinemia. , 2017, , 367-370.		1
905	Thalidomide for myeloma: still here?. Lancet Haematology,the, 2018, 5, e439-e440.	4.6	1
906	Optimizing therapy in bortezomib-exposed patients with multiple myeloma. Expert Review of Hematology, 2018, 11, 463-469.	2.2	1
907	Discrepancies of current recommendations in breast cancer follow-up: a systematic review. Breast Cancer, 2019, 26, 681-686.	2.9	1
908	Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greeceâ€”the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG). Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 491-501.	1.4	1
909	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction. Journal of Clinical Medicine, 2020, 9, 3201.	2.4	1
910	Response of an oncology unit in the midst of the COVID-19 outbreak. Journal of Oncology Pharmacy Practice, 2020, 26, 1947-1952.	0.9	1
911	A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e629-e644.	0.4	1
912	Cardiac amyloidosis presenting with coronary artery embolization. Reviews in Cardiovascular Medicine, 2021, 22, 883.	1.4	1
913	Management of patients with difficult-to-treat multiple myeloma. Future Oncology, 2021, 17, 2089-2105.	2.4	1
914	Referral for Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer to a Multidisciplinary Board: Patterns, Management and Outcomes. Cancer Management and Research, 2021, Volume 13, 5941-5955.	1.9	1
915	Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines. Blood, 2018, 132, 3244-3244.	1.4	1
916	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS). Blood, 2019, 134, 3126-3126.	1.4	1
917	A Molecular Signature of Three tRNA-Derived RNA Fragments May Discriminate Smoldering from Symptomatic Multiple Myeloma Patients. Blood, 2019, 134, 5528-5528.	1.4	1
918	Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone.. Blood, 2007, 110, 191-191.	1.4	1

#	ARTICLE	IF	CITATIONS
919	Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2014, 124, 4769-4769.	1.4	1
920	Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years. <i>Blood</i> , 2016, 128, 2957-2957.	1.4	1
921	Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important. <i>Blood</i> , 2016, 128, 3310-3310.	1.4	1
922	Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy. <i>Blood</i> , 2016, 128, 3340-3340.	1.4	1
923	Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003. <i>Journal of Clinical Oncology</i> , 2013, 31, 8583-8583.	1.6	1
924	Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for crossover. <i>Journal of Clinical Oncology</i> , 2014, 32, 8593-8593.	1.6	1
925	The Prognostic Role of Protein Expression in Pregnancy Associated Breast Cancer: A Literature Review. <i>Journal of Cancer Science and Clinical Therapeutics</i> , 2020, 04, .	0.3	1
926	Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients. <i>Blood</i> , 2013, 122, 1867-1867.	1.4	1
927	Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 3461-3461.	1.4	1
928	Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results. <i>Blood</i> , 2014, 124, 2112-2112.	1.4	1
929	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. <i>Blood</i> , 2015, 126, 4188-4188.	1.4	1
930	Ibrutinib for rituximab-refractory Waldenström macro-globulinemia. <i>Oncotarget</i> , 2018, 9, 12536-12537.	1.8	1
931	Clinical and biological implications of Hippo pathway dysregulation in sarcomas. <i>Forum of Clinical Oncology</i> , 2019, 9, 11-16.	0.2	1
932	Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN). <i>Blood</i> , 2019, 134, 1868-1868.	1.4	1
933	Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis. <i>Blood</i> , 2019, 134, 1894-1894.	1.4	1
934	ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm. A Cohort Study by the Hellenic GU Cancer Group. <i>Current Oncology</i> , 2021, 28, 4474-4484.	2.2	1
935	Evaluation of Efficacy and Immune Modulation Associated with the Addition of IMiDs to Daratumumab Backbone in Patients Refractory to Both Drug Classes. <i>Blood</i> , 2021, 138, 1668-1668.	1.4	1
936	Prothymosin $\hat{\pm}$ and Its C-Terminal Immunoreactive Decapeptide Show no Evidence of Acute Toxicity: A Preliminary in Silico, in Vitro and in Vivo Investigation. <i>Current Medicinal Chemistry</i> , 2021, 28, .	2.4	1

#	ARTICLE	IF	CITATIONS
937	Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). <i>Blood</i> , 2021, 138, 1634-1634.	1.4	1
938	Carfilzomib-Induced Hypertension Is Mediated By Ion Channel Dysregulation in the Kidneys; The Potent Role of AMP-Activated Kinase $\alpha$ . <i>Blood</i> , 2020, 136, 34-35.	1.4	1
939	Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment. <i>Blood</i> , 2020, 136, 25-25.	1.4	1
940	Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis. <i>Blood</i> , 2020, 136, 33-33.	1.4	1
941	Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts. <i>Blood</i> , 2020, 136, 20-21.	1.4	1
942	T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study. <i>Blood</i> , 2020, 136, 28-28.	1.4	1
943	Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study. <i>Hemato</i> , 2022, 3, 188-203.	0.6	1
944	Post-protocol therapy and informative censoring in the CANDOR study – Authors' reply. <i>Lancet Oncology</i> , The, 2022, 23, e98.	10.7	1
945	Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100953.	0.6	1
946	Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone. <i>Blood</i> , 2020, 136, 39-41.	1.4	1
947	Advances in Gynecological Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6152.	4.1	1
948	CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8070-TPS8070.	1.6	1
949	Irreversibility of drug resistance in VAD-refractory myeloma. <i>American Journal of Hematology</i> , 1992, 40, 154-155.	4.1	0
950	Current Treatment of Relapsed Ovarian Carcinoma. <i>Current Cancer Therapy Reviews</i> , 2006, 2, 211-221.	0.3	0
951	Squamous Cell Esophageal Carcinoma as a Second Primary Malignancy in a Woman with Epithelial Ovarian Cancer. <i>Digestive Diseases and Sciences</i> , 2007, 52, 3099-3101.	2.3	0
952	Editorial Comment on: New treatment approaches for prostate cancer based on peptide analogues. <i>European Urology</i> , 2008, 53, 899-900.	1.9	0
953	DIAGNOSIS, RISK-STRATIFICATION, AND MANAGEMENT OF SOLITARY PLASMACYTOMA. , 0, , 150-163.		0
954	Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies. <i>Oncology Reviews</i> , 2009, 3, 173-186.	1.8	0

#	ARTICLE	IF	CITATIONS
955	Intravenous pamidronate for myeloma bone disease: can the dose be lowered?. Lancet Oncology, The, 2010, 11, 913-914.	10.7	0
956	High dose melphalan in primary systemic amyloidosis: status quo?. Leukemia and Lymphoma, 2010, 51, 2149-2151.	1.3	0
957	Zoledronic acid for all patients with newly diagnosed multiple myeloma?. Lancet Oncology, The, 2011, 12, 711-712.	10.7	0
958	New Insights in Waldenström's Macroglobulinemia. , 2012, , 223-236.		0
959	Waldenström's Macroglobulinemia. , 2013, , 681-699.		0
960	Reply to D.L. Cooper. Journal of Clinical Oncology, 2015, 33, 2926-2927.	1.6	0
961	The role of ibrutinib in Waldenström macroglobulinemia. Expert Opinion on Orphan Drugs, 2018, 6, 85-89.	0.8	0
962	Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis. Leukemia and Lymphoma, 2020, 61, 2246-2249.	1.3	0
963	Mutation-dependent treatment approaches for patients with complex multiple myeloma. Expert Review of Precision Medicine and Drug Development, 2021, 6, 189-201.	0.7	0
964	Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2021, 39, e14558-e14558.	1.6	0
965	CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience. Medical Sciences (Basel), Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 2.9	2.9	0
966	Managing complications secondary to Waldenström's macroglobulinemia. Expert Review of Hematology, 2021, 14, 1-12.	2.2	0
967	Treatment of Multiple Myeloma. , 2004, , 137-157.		0
968	Prognostic Significance of Magnetic Resonance Imaging (MRI) of Bone Marrow (BM) in Patients with Multiple Myeloma (MM) Undergoing Treatment with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplantation (ASCT).. Blood, 2006, 108, 3095-3095.	1.4	0
969	Diffuse MRI Pattern of Marrow Infiltration Correlates with Suppressed Bone Formation and Increased Incidence of Vertebral Fractures in Multiple Myeloma.. Blood, 2006, 108, 5018-5018.	1.4	0
970	Thalidomide Based Regimens (TBR) for Relapsed/Refractory Multiple Myeloma Patients: Long Term Follow Up, Unmaintained Remissions and Disease Control after Subsequent Treatments.. Blood, 2007, 110, 4812-4812.	1.4	0
971	The International Prognostic Scoring System for Waldenström's Macroglobulinemia (ISSWM) Is Applicable in Patients Treated with Rituximab-Based Regimens.. Blood, 2007, 110, 3615-3615.	1.4	0
972	Symptomatic Waldenström's Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome.. Blood, 2007, 110, 4730-4730.	1.4	0

#	ARTICLE	IF	CITATIONS
973	High Bone Turnover and Increased Angiogenesis Cytokines in Patients with POEMS Syndrome.. Blood, 2007, 110, 3525-3525.	1.4	0
974	Primary Therapy of Waldenstrom's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network.. Blood, 2009, 114, 2886-2886.	1.4	0
975	Waldenström's Macroglobulinemia Associated with Cryoglobulinemia: Pathogenetic, Clinical, and Therapeutic Aspects. , 2012, , 277-283.		0
976	Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003.. Journal of Clinical Oncology, 2013, 31, 8528-8528.	1.6	0
977	Genetic Variations In TLR-4/TIRAP Genes Influence Response To IMiDs-Based Regimens and Conventional Chemotherapy In Patients With Multiple Myeloma. Blood, 2013, 122, 1861-1861.	1.4	0
978	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). Blood, 2013, 122, 3185-3185.	1.4	0
979	Circulating Levels of Angiogenic Cytokines in Waldenström's Macroglobulinemia: Clinical Correlations. Current Angiogenesis, 2014, 2, 104-109.	0.1	0
980	Platinum-based therapy and oral cyclophosphamide as salvage therapy in heavily pretreated metastatic castrate resistant prostate cancer (mCRPC) patients with poor performance status and bulky/LN/visceral disease.. Journal of Clinical Oncology, 2014, 32, e16096-e16096.	1.6	0
981	Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International Study. Blood, 2014, 124, 3488-3488.	1.4	0
982	Elevated Involved Light Chains Discordant to the Increase of the Involved Heavy Chains Identifies a Subset of Multiple Myeloma Patients with Worse Outcome. Blood, 2014, 124, 2132-2132.	1.4	0
983	High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease. Blood, 2014, 124, 2028-2028.	1.4	0
984	Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) Amyloidosis. Blood, 2014, 124, 2029-2029.	1.4	0
985	The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma. Blood, 2014, 124, 3462-3462.	1.4	0
986	Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents. Blood, 2014, 124, 3464-3464.	1.4	0
987	Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents. Blood, 2014, 124, 2130-2130.	1.4	0
988	Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy. Blood, 2014, 124, 2115-2115.	1.4	0
989	Translating Findings of Proteasome Inhibitors Effects from the in Vivo Drosophila Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and Carfilzomib. Blood, 2014, 124, 4814-4814.	1.4	0
990	Circulating Adamts-13 Is Reduced in Patients with Waldenstrom's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand Factor. Blood, 2014, 124, 5741-5741.	1.4	0



#	ARTICLE	IF	CITATIONS
991	Pomalidomide – An Appraisal of Its Clinical Development and Role in the Treatment of Relapsed/Refractory Multiple Myeloma. <i>European Oncology and Haematology</i> , 2015, 11, 109.	0.0	0
992	Bevacizumab (BEV) with or after chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (PROC): Exploratory analyses of the AURELIA trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5551-5551.	1.6	0
993	The patient with myeloma. , 2015, , 1276-1291.		0
994	The Simultaneous Accumulation of the Extremely Cytotoxic Interstrand Cross-Links and Double-Strand Breaks Contributes to the Successful Anti-Myeloma Therapy; The Effect of DNA Repair Inhibitors. <i>Blood</i> , 2015, 126, 4177-4177.	1.4	0
995	Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2015, 126, 1834-1834.	1.4	0
996	Bortezomib-Based Triplets Are Associated with a High Probability of Dialysis Independence and Rapid Renal Recovery in Newly Diagnosed Myeloma Patients with Severe Renal Failure or Those Requiring Dialysis. <i>Blood</i> , 2015, 126, 1832-1832.	1.4	0
997	Analysis of Molecular-Cellular Responses to Proteasome Inhibitors in Multiple Myeloma Patients; A Translational Approach of Proteasome Inhibitors In Vivo Effects from the Drosophila Experimental Model to Humans. <i>Blood</i> , 2015, 126, 3250-3250.	1.4	0
998	Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 3045-3045.	1.4	0
999	Prospective Evaluation of Blood Pressure Monitoring and Baroreceptor Reflex Sensitivity (BRS) in Patients with AL Amyloidosis: Prognostic and Pathophysiologic Implications. <i>Blood</i> , 2015, 126, 3054-3054.	1.4	0
1000	Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease. <i>Blood</i> , 2015, 126, 4251-4251.	1.4	0
1001	Real-World Prospective Evaluation of Different Geriatric Assessment Tools in Unselected Elderly Patients with Symptomatic Myeloma. <i>Blood</i> , 2015, 126, 4242-4242.	1.4	0
1002	Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8031-8031.	1.6	0
1003	Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group. <i>Blood</i> , 2016, 128, 4488-4488.	1.4	0
1004	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. <i>Blood</i> , 2016, 128, 4414-4414.	1.4	0
1005	European Post-Approval Safety Study (PASS) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety, Including SPM, in a Large Cohort of Patients Treated with Lenalidomide, Thalidomide, and Bortezomib. <i>Blood</i> , 2016, 128, 3331-3331.	1.4	0
1006	Indirubins: A Potential Therapeutic Target in Multiple Myeloma. <i>Blood</i> , 2016, 128, 3259-3259.	1.4	0
1007	Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents. <i>Blood</i> , 2016, 128, 4490-4490.	1.4	0
1008	Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment. <i>Blood</i> , 2016, 128, 3311-3311.	1.4	0

#	ARTICLE	IF	CITATIONS
1009	Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib. <i>Blood</i> , 2016, 128, 4500-4500.	1.4	0
1010	Chromatin Histone Modifying and DNA Repair Inhibition Enhances the Anti-Myeloma Activity of Melphalan. <i>Blood</i> , 2016, 128, 4437-4437.	1.4	0
1011	Time to deterioration (TTD) in health-related quality of life (HRQoL) with carfilzomib plus dexamethasone (Kd56) versus bortezomib plus dexamethasone (Vd) in the ENDEAVOR trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e20011-e20011.	1.6	0
1012	Randomized phase 3 trial of ibrutinib/rituximab vs placebo/rituximab in Waldenström's macroglobulinemia.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8003-8003.	1.6	0
1013	Carfilzomib Induces Acute Endothelial Dysfunction Which Correlates with the Occurrence of Cardiovascular Events. <i>Blood</i> , 2018, 132, 3247-3247.	1.4	0
1014	Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment. <i>Blood</i> , 2019, 134, 1877-1877.	1.4	0
1015	Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis. <i>Blood</i> , 2019, 134, 1842-1842.	1.4	0
1016	Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Blood</i> , 2021, 138, 4202-4202.	1.4	0
1017	What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience. <i>Current Oncology</i> , 2021, 28, 4862-4873.	2.2	0
1018	IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure. <i>Blood</i> , 2020, 136, 12-12.	1.4	0
1019	A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. <i>Blood</i> , 2020, 136, 8-8.	1.4	0
1020	Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study. <i>Blood</i> , 2020, 136, 19-20.	1.4	0
1021	Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study. <i>Blood</i> , 2020, 136, 29-29.	1.4	0
1022	Derivation and Validation of a Predictive Score for Disease Worsening Inpatients with COVID-19. <i>Blood</i> , 2020, 136, 26-27.	1.4	0
1023	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
1024	Carfilzomib-Induced Cardiotoxicity in an In Vivo Model of Aging. <i>Blood</i> , 2020, 136, 18-18.	1.4	0
1025	DUPLICATE: Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.4	0
1026	Daratumumab for Immunoglobulin Light Chain Amyloidosis. <i>Touch Reviews in Oncology &amp; Haematology</i> , 2021, 17, 79.	0.2	0

#	ARTICLE	IF	CITATIONS
1027	Molecular testing for prostate cancer in Greek patients.. Journal of Clinical Oncology, 2022, 40, 170-170.	1.6	0
1028	The COMPASS-COVID-19-ICU Study: Identification of Factors to Predict the Risk of Intubation and Mortality in Patients with Severe COVID-19. Hemato, 2022, 3, 204-218.	0.6	0